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Abbreviation Definition
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Osteoarthritis of  the hip is a common, debilitating and 
symptomatic joint disease. The disabling symptoms 
can be successfully treated with a total hip replacement 
(THR). It is known that the majority of  patients do 
well following surgery, however some patients will need 
further surgery on the same or on the other hip or die 
prematurely in the perioperative period. The causes 
leading to further surgery for patients and the risks for 
mortality are multifactorial. The following are important 
factors in defining the risk for an individual patient: 
indication for surgery, complexity of  operation, patient 
age, medical comorbidities, physical activity and socio-
economic factors, types of  implants used and surgical 
techniques employed, as well as perioperative protocols 
and post-operative treatment.
The research questions for this project were: 
1. Has there been a change in patient-related, surgery-
related and socioeconomic factors in patients 
undergoing elective hip replacements and have the 
various outcome parameters evolved? 
2. Is there an association between self-reported 
health status and mortality following elective hip 
replacement? 
3. Have patients who underwent THR a better 
relative survival than the general survival and is this 
influenced by the diagnosis for which the THR was 
undertaken? 
4. What is the long-term risk of  subsequent surgery on 
the same or the opposite hip and risk of  mortality 
after an elective primary THR? Is there an influence 
of  patient-related, surgery-related and socio-
economic factors on subsequent surgery and dying? 
Patient level data concerning many of  these factors 
are available in the Swedish Hip Arthroplasty Register 
and administrative databases of  the National Board 
of  Health and Welfare and Statistics Sweden. This 
information was linked into a single research database. 
Abstract
The principles of  relative survival analysis and multi-
state analysis with multivariable regression for statistical 
analysis were used. It was decided to study patients 
undergoing elective THR between 01/01/1999 and 
31/12/2012.
Most patients were operated because of  primary 
osteoarthritis and the proportion of  patients with this 
indication increased further during the period of  study 
at the expense of  a decreasing number of  patients 
with inflammatory arthritis.. The practice of  elective 
THR has changed during the study-period, and there 
has been a reduction in 30- and 90-day mortality, an 
overall improvement of  revision rates and patients have 
reported improved satisfaction and outcomes. Worse 
health status according to the EQ-5D before THR 
was associated with higher mortality up to five years 
after surgery. Patients with a THR had an improved 
relative survival compared to an age- and sex-matched 
population. A diagnosis-specific differentiation of  
relative survival rates post-THR favored patients with 
hip osteoarthritis. Higher Elixhauser comorbidity index, 
lower level of  education and being widow or single had 
an adverse effect on survival. 
The lifetime risk for bilateral surgery, revision and 
death was identified using the longitudinally collected 
data. Despite some changes in practice, the long-term 
outcome following THR has improved as surgical 
practices have evolved. A worse self-reported health 
status is associated with increased mortality in the 
medium-term. Overall, patients undergoing elective 
THR will have a better relative survival and a low risk 
of  revision. The risk of  receiving further surgery on the 
same or on the other hip is multifactorial and patients 
are twice as likely to have their other hip replaced than 
to die during the study-period. Performing a primary 
arthroplasty on the contralateral hip is 7 times more 
likely than a revision procedure on the first implanted 
hip. 
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Total hip replacement
Osteoarthritis (OA) of  the hip is a common debilitating 
and symptomatic joint disease, and affects up to 25% 
of  the population over 85 years of  age (1). The causes 
of  OA are multifactorial and the global burden of  
the disease is increasing (2). If  a trial of  non-surgical 
treatment with lifestyle modification (weight control, 
exercise, walking aids) and analgesia fails to provide 
the patient with the desired goals of  reducing pain, 
regaining mobility and improving health-related quality 
of  life then a surgical intervention can mitigate the 
disabling symptoms (3–6). The decision when and 
whether to proceed to surgery needs to based on a 
discussion between surgical team and patient and 
follow the principles of  shared decision making (7).
The irreversible operation of  total hip arthroplasty 
consists of  replacing the affected hip with an artificial 
ball and socket joint. Sir John Charnley has widely being 
recognised of  popularising successful hip replacement 
following earlier unsuccessful attempts (8–10). The 
procedure is considered to be one of  the most successful 
and cost-effective surgical interventions and has been 
named “the operation of  the century” (11, 12). Several 
publications and national arthroplasty registers have 
confirmed that survivorship of  many types of  implants 
at 10 years is in excess of  95% (13–15). However, it 
is also well known that in a minority of  patients the 
operation does not provide the expected outcome. 
Despite this, the future demand for primary as well as 
revision surgery has been described and most authors 
anticipate an inexorable increase in incidence (16–22).
The success of  a hip replacement cannot solely be 
defined by the absence of  a revision procedure (23). 
From a patient’s point of  view the intervention is 
considered successful if  there is an absence of  pain 
related to the joint, a re-establishment of  mobility and 
a long-term uneventful retention of  the implanted 
joint (24). A less successful outcome or failure of  the 
surgical intervention could be characterized by persisting 
poor function, failure to completely relieve the pain, 
inability to fulfil patient expectations and the occurrence 
of  adverse events (complications). Complications may 
occur during or immediately after the surgical procedure 
or in the longer term. They may necessitate admission to 
hospital. The complication may lead to further surgery 
on the hip including revision surgery to replace one or 
Background and introduction
more components and in a small number of  cases the 
patient may die as a result (25). 
A great deal is known with regard to the demand and 
need for redo-operations (revisions) where one or 
more of  the components of  the artificial joint need to 
be exchanged, removed or added. Less is known about 
the final outcome of  the intervention (16, 17, 19, 21). 
It is recognized that a small proportion of  patients will 
require readmission to hospital within 30-or 90-days of  
the first hip operation for treatment of  adverse events 
arising as a consequence of  the surgical intervention. In 
addition, some patients might require re-operation(s) on 
the hip at some later point for treatment of  a variety 
of  conditions such as a wound problem, superficial or 
deep infection, dislocation, implant loosening and other 
reasons. A proportion of  these will require removal 
and re-implantation of  one or both components on 
one or more occasions. These subsequent contacts 
with healthcare providers following the original surgery 
are used as quality indicators for the surgery in some 
countries. 
The number of  patients who have recurrent problems 
resulting in repeated readmissions and reoperations is 
difficult to track in any healthcare system and is not 
completely known. Additionally, the clinical outcome 
for these patients with regard to their perception of  
pain, their functional performance and overall mobility 
are also unknown. It is acknowledged that the results of  
revision surgery are less likely to be as good as the first 
operation and patients who require multiple procedures 
are far less likely to have a pain-free, well-functioning 
hip (26–29). In addition, with every surgical procedure 
there is a finite risk of  death, the highest risk being in 
elderly, unfit patients. The additional mortality risk to 
patients who have early problems after surgery is not 
known. A graphic representation of  the convoluted 
pathway followed by the patients after the surgery is 
represented in figure 1.
The causes leading to further hospital admissions for 
patients are likely to be multifactorial (30). The following 
factors are important in defining the risk of  readmission 
for an individual patient: preoperative functional state, 
indication for surgery, complexity of  operation, patient 
age, medical comorbidities, physical activity and socio-
economic factors, types of  implants used, surgical 
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techniques employed, perioperative protocols and post-
operative treatment. The influence of  a preoperative 
function score on outcomes has been described in two 
prospective cohort studies; patients who score worse 
preoperatively are shown to have a poorer outcome at 
six months and two years (31, 32).
With the predicted increase in demand and the rise in cost 
for procedures it is important that the factors important 
in patient care are optimised and the multifactorial 
causes leading to suboptimal outcomes are addressed, 
where feasible, in order to avoid unnecessary additional 
and avoidable costs. The Getting It Right First Time 
(GIRFT) initiative can be considered an example of  a 
national approach to optimising outcomes and reduce 
costs (33, 34).
Information concerning many of  these factors is 
available in the Swedish Hip Arthroplasty Register 
(SHAR) and databases of  the National Board of  Health 
and Welfare and Statistics Sweden. It is possible to study 
their potential interactions and associations with the 
longitudinal outcome by combining the information 
into a single study database.
Registers, the quality registers, the 
Swedish Hip Arthroplasty Register and 
arthroplasty registers
The word “register” stems from Latin registrum, meaning 
‘things recorded’ and is used in epidemiology for a file 
of  data, related to a population base (35).
Figure 1: Convoluted pathway of  a patient under going 
primary THR (adapted from Cnudde et al (64))
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Ernest Amory Codman (1869–1940), considered 
father of  the registers, developed his bone sarcoma 
register in the beginning of  the 20th century as part 
of  an assessment of  his outcomes and to develop an 
improved strategic plan for his future patients using 
the “If  not, why not” principle and the “End Result 
Idea” (36, 37). He could not have realized that long 
after his death his contributions would be considered of  
immense value and instrumental in the understanding of  
the way patients, surgeons, implant manufacturers and 
decision-makers would use the current registers (36). In 
an editorial, The Lancet describes the effect of  national 
disease registries on reduction of  cost and improving 
outcomes through comparison, identification and the 
adoption of, best practice (38). This editorial was based 
on the work of  Larsson et al. where they describe 
the effect of  registries on improved health outcomes, 
having collected information from 13 leading registries 
in five countries (39).
Sweden is considered to be one of  the pioneering 
countries in register work and developed the ‘Quality 
Registers’ (QR) to ‘examine and improve the delivery of  
the healthcare’ (40, 41). In recognition of  the importance 
of  the QR’s there was an extra-funding agreement in 
the period 2012–2016 with additional co-funding by the 
Swedish government (70%) and Swedish Association of  
Local Authorities and Regions (30%). 
The SHAR was set up in 1979 to study all kinds of  
reoperations including procedures where the implant or 
its parts are exchanged or removed (revisions). Gradually 
and over the years there have been changes in the 
content and the methods of  data collection. Since 1992 
the orthopaedic departments of  the various hospitals 
within Sweden (University, county, rural and private 
hospitals) report all primary surgeries and subsequent 
reoperations to the SHAR based on the Personal Identity 
Number (PIN) and laterality. The evolution of  the 
SHAR was described by Kärrholm in 2010 (42). There 
is a continuous and on-going assessment and validation 
of  data quality and completeness. There are up to six 
steps in the validation process with the first three steps 
being routine practice for all primary surgeries (Table 1).
It is widely recognised that the pioneering work of  
the SHAR and its acceptance within the orthopaedic 
community has led to changes in practice that has 
resulted in the revision rate following hip replacement 
surgery in Sweden being amongst the lowest in the world. 
This has been accomplished by the diligent follow-up of  
patients with feedback of  outcomes to the providers of  
the healthcare along with post market surveillance of  
individual implant performance. The SHAR has three 
main tasks related to hip replacement surgery: 
1. Analysing healthcare institutions and their activities 
2. Stimulating continuous clinical improvement 
3. Performing clinical research
In addition, the SHAR manages post-market surveillance 
of  implants. Since its inception the SHAR has not 
remained static, but has responded to changing demands 
and expectations with the introduction of  innovative 
new performance tools. One major development was 
the introduction of  the Patient-reported Outcome 
Measures (PROMs) program, giving a voice to the 
patients in healthcare performance evaluation (43–45). 
As part of  the quality control and feedback mechanism 
the annual report from the SHAR publishes a “Clinical 
Value Compass” for each and every hospital performing 
THR (https://registercentrum.blob.core.windows.net/
shpr/r/Annual-Report-2016-B1eWEH-mHM.pdf). 
This graphical representation provides a comparison 
of  the performance on eight quality indicators of  every 
hospital in Sweden with the national average (Fig 2). 
The eight quality indicators are selected from mortality 
figures, reoperation data, revision data, PROMs, and 
data quality. It has now been suggested that a shared 
decision-making (SDM) instrument should be developed 
in an attempt to further integrate patients’ wishes and 
expectations with the surgeons’ expertise (46–48). The 
Table 1.  Six steps in the validation process of SHAR data
1 Logical control at the web-based entry
2 Control of completeness using the comparison of SHAR database and the hospital’s own patients administrative database
3 Control of completeness between the SHAR database and the national patient register
4 Manual capture of all reoperations with linkage to the primary surgery
5 Routine monitoring of the different hospitals using site visits by the register co-ordinators
6 Targeted validating studies (e.g. infections/periprosthetic fractures)
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first step in building such an instrument is to assemble 
the necessary data from different sources. This involves 
linking the SHAR database with databases of  other 
governmental agencies.
Satisfaction
Pain relief
after 1 year
EQ−5D gain
after 1 year   
Adverse events
within 90 days
Completeness
Reoperation
within 2 years
     5−year implant
     survival
10−year implant
survival
Value compass − national average
Quality indicator
Figure 2: Average Clinical Value Compass for the Swedish 
Orthopaedic units (adapted from Annual report 2016 
(SHAR))
The success of  the SHAR has led to the development 
of  regional and national registers in other countries 
and a collaboration between different established 
registers around the globe (Nordic Arthroplasty 
Register Association (NARA), Network of  Orthopaedic 
Registries of  Europe (NORE), International Society of  
Arthroplasty Registries (ISAR)). As a result there are 
many orthopaedic and other medical interventions and 
diagnoses that are now monitored by Registries using 
similar models. In a recent article, Berry describes 
what can be learnt from the arthroplasty registers 
by collating observations made from the American, 
Australian, England & Wales, New Zealand, Swedish 
national joint registries and the Kaiser Permanente 
Joint Registry (49). The Scandinavian countries each 
have established and well-functioning joint registries 
and the Nordic Countries have been pooling some of  
their data in a collaboration to analyse specific issues 
under the NARA banner, set up in 2007 (50). Within 
the United Kingdom, the National Joint Register (NJR) 
was established in 2003 as a response to the Capital Hip, 
3M® issue (51). The NJR is now the biggest register 
in the world, and has now over 2.3 million entries 
covering hip, knees, shoulders, elbows and ankles. The 
Australian Orthopaedic Association National Joint 
Register (AOANJRR) was initiated in 1999 and has over 
1.1 million entries. The American Joint Replacement 
Register (AJRR) is one of  the more recent national joint 
registers, expanding quickly and driven by the need to 
improve outcomes and quality of  joint replacement 
surgery within the USA. The International Society of  
Arthroplasty Register (ISAR), founded in 2004, has 
a goal to utilize the strength of  cooperation, sharing 
of  information, and further enhance the capacity of  
individual registries (Table 2).
In line with the initial ideas of  Codman, the main aim 
of  the arthroplasty registers is to improve outcomes 
following joint replacement surgery. Malchau et al. have 
suggested that further innovation within arthroplasty 
could well benefit from register-nested trials (52, 
53). Gray described the strength of  the registries as 
a knowledge-development tool and concludes that 
besides the assessment of  long-term safety of  implants 
they can also contribute to improvement in patient care 
and reduction of  waste as well as providing a resource 
for epidemiological studies and research into long-term 
outcomes (54).
Studies based on a valid interpretation of  high quality 
data can be considered as an extra value from the 
registers. Opponents as well as supporters of  registers 
have published their critiques (55–59). Register-based 
research and RCT’s fulfill different functions and should 
be considered as being complementary to each other. 
Register-based studies are observational in nature and 
cannot prove or disprove causality. It is likely that 
the future will focus on register-nested trials as an 
innovative way to evaluate new implants and techniques. 
Many reports have been describing the positive effects 
of  arthroplasty registers and the observed improved 
outcomes for patients as a result of  the ongoing 
feedback mechanism (60–63).
The National Board for Health and 
Welfare (NBHW-Socialstyrelsen)
This government agency is working under the auspices of  
the Ministry of  Health and Social Affairs (http://www.
socialstyrelsen.se/english). It is the main administrative 
authority dealing with healthcare in Sweden. Its 
tasks are mainly providing guidelines and managing 
healthcare regulation. The Swedish government has set 
up health data registers (HDR) and it is mandatory for 
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all healthcare providers to report data to these centrally 
organized HDR. The Cancer Register (1958), The Cause 
of  Death Register (1961), the National Patient Register 
(NPR, 1964), The Inpatient Care Operations Register 
(1997) and the Drug Register (2005) do contain a wealth 
of  information and are all part of  the governmental 
HDRs. The data available on these registers has been 
linked to the SHAR database and will be used for 
this study looking at pre-existing comorbidity and 
readmissions mainly from the NPR.
Statistics Sweden (SCB- Statistiska 
Centralbyrån)
Another government agency (www.scb.se) containing 
data relevant to the analysis of  arthroplasty outcome 
has roots dating back to the 17th century (1686). The 
parishes of  the Church of  Sweden were ordered to 
start keeping records on the Swedish population. The 
current name (SCB) became official in 1858, after the 
organization was named Tabellverket (Office of  Tables) 
in 1749. According to Swedish law (Official Statistics 
Act 2001:100) there must be official statistics for general 
information, investigation and research. The agency is 
responsible for collecting information on the Swedish 
population and providing official statistics to inform 
decision-making, promote debate and allow research. 
The overall goal of  the agency is to produce official 
statistics of  good quality and it strives to be a world-
class leader in refining available data into statistical 
sound and reliable information for researchers, the 
private sector and the government. They have provided 
us with individual data on baseline demographics and 
socioeconomic status.
Linked database (64)
Bozic et al state that “the seamless integration of  data, 
combined with the analytics to see and communicate 
insightful patterns within it, will be an invaluable tool 
for improving quality, reducing cost, and advancing 
research” (65).
The use of  linkage of  various databases is used 
increasingly both in the medical world as well as in 
Table 2.  Example of joint replacement registries
Country Start date Number  
of THR
PROMs Revision rate %  
@10yrs or KM 
implant surv
Owner
SHAR Sweden 1979 455,348 V 97% KM surv Regional/government
NJR UK 2003 895,292 (31/12/16) V 5.21% Government
AOANJRR Australia 1999 545,831 (31/12/16) NO
5.1% 
OA only
Orthopaedic Association
AJRR USA 2009 169.060 (31/12/15) V NA Freestanding
LROI Netherlands 2007 227,301 (31/12/16) V
4.6% 
@8yrs
Orthopaedic Association
NZJR New Zealand 1997 110,208 (31/12/15) V
93.50% 
KM surv
Orthopaedic Association
DHR Denmark 1995 161,968 (31/12/16) NO 92% Danish Regions
FAR Finland 1980 188,273 (30/1O/17) NO 12.3% Government
NRL Norway 1987 211,234 (31/12/16) NO
91.50% 
KM surv
Regional
NARA Scandinavia 2007 NA NA NA Independent
ISAR International 2004 NA NA NA Independent
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other areas. The databank, developed through Swansea 
University (UK), states that it has developed a research-
ready platform using data from primary care, secondary 
care as well as social services (66, 67). Large amounts 
of  relevant, quality data are a powerful tool, and the 
amalgamation of  these data sets will provide new 
insights and contribute to the development and analysis 
of  new medical devices, techniques and medication as 
well as help with the analysis of  the existing treatment 
modalities.
As there is more and more evidence that the outcome 
following joint replacement surgery can be influenced 
by socio-economic factors as well as comorbidity it is 
extremely important to include these variables in the 
analysis of  outcomes (59, 68–71). In the past registries 
have been criticized for not making adjustments for 
comorbidity and socioeconomic status as it is believed 
that they can be associated with poorer outcomes (72). 
These variables are not normally captured within the 
databases of  the SHAR, but this specific information 
can be requested from and is available within different 
government databases. Some previous research projects 
with roots within the SHAR have been able to combine 
the necessary information following selective linkage. We 
therefore felt combining the variables of  socioeconomic 
data and comorbidities in one single validated research 
database could well be advantageous. In the UK, the 
strategic plan of  the NJR focuses on the ability to link 
their database with other governmental databases. This 
should achieve a strengthening and deepening of  the 
study quality by increasing the number of  variables and 
decreasing some of  the current unknown variables, not 
routinely recorded within the NJR. Statisticians from 
the Bristol group have developed and tested formulas 
and codes to enable probabilistic matching based on 
available patient information details, in the absence of  
a PIN (73). 
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1. To describe the linkage process to facilitate data expansion into a single research database, the different sources 
of  data, and to study the ethical framework and possible applications of  the research database. 
2. To define time trends in patient-related and procedure-related factors, that may influence outcomes within the 
study period. 
3. To study the association between pre-operative, self-reported health and midterm mortality.
4. To compare survival patterns of  patients undergoing elective THR with the general population using the 
techniques of  relative survival and life tables. 
5. To quantify the proportion of  patients having surgery on the ipsi- and/or contralateral hip following the initial 
hip replacement, determine and explore factors leading to an increased risk of  further surgery. To study the 
association between patient-related, socio-economic and procedure-related factors including surgical operation 
and the type of  implant used, and implant and patient survival.
Study objectives 
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Patients and methods 
The Swedish Register system is in a unique position to 
be able to reliably track the entire patient pathway. It 
enables detailed modelling of  the patients’ journey after 
a hip replacement with regard to confounding variables 
such as socio-economic status, general health and well-
being, comorbidity, patient-related variables, surgery-
related variables, hospital-related details and other 
variables from a variety of  reliable sources. 
As one of  the oldest existing national registers SHAR 
has the advantage of  maturity over the more recently 
developed registers, especially in the study of  long-
term or longitudinal outcome. Using the unique PIN, 
data from the SHAR could be linked with health and 
socio-economic data and variables using the databases 
under the auspices of  the National Board of  Health and 
Welfare and Statistics Sweden (table 3).
1. Swedish Hip Arthroplasty Register (SHAR): 
contains relevant information regarding laterality, 
patient age at time of  operation, diagnosis, 
characteristics of  the surgery, postoperative compli-
cations, outcome measurements (42).
2. Statistics Sweden (SCB): contains baseline demo-
graphics, socio-economic status, completed level of  
education, unemployment record, income (both on 
a household and on an individual basis), residence 
(municipality), sickness record, rehabilitation record, 
country of  birth.
3. National Board of  Health and Welfare (NBHW) 
and the Swedish National Patient Register (NPR): 
contain details of  medical comorbidities, admissions 
to hospital care, discharge diagnoses (ICD-9 and ICD-
10), dates of  admissions and discharges.
Following ethical approval from the Regional Ethical 
Review Board (Gothenburg dnr 271-14) data from the 
SHAR was merged with data from the National Board of  
Health and Welfare and Statistics Sweden using the unique 
10-digit PIN maintained by the Swedish Tax Office 
(Skatteverket) (74). Data on every primary hip replacement 
recorded in the SHAR was forwarded with the PIN and 
laterality (right or left) to the NBHW where requested 
variables were added. Subsequently this combined data 
was returned with a serial number (without PIN) to the 
SHAR and forwarded to the SCB with serial number and 
PIN to merge the additional data. This completed dataset 
is then forwarded to the SHAR without PIN (Fig 3) (64). 
Figure 3: Linkage process between the SHAR, NBHW and the SCB using the PIN number and adding of  a serial 
number providing anonymised data (adapted from Linking Swedish health data registers to establish a research database 
and a shared decision-making tool in hip replacement by Cnudde et al. (64))
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Consequently a master research database comprising 
79 files, totalling 96 gigabytes was constructed 
containing information from patients undergoing hip 
replacements operated in the time period 1992–2014. 
There were 279,173 primary procedures recorded in 
230,424 patients. Of  these, 15,842 patients went on 
to undergo 16,501 reoperations. Data was stored on 
encrypted servers (Secure Online Data Access-SODA) 
that could only be accessed by researchers involved in 
the project. Data was structured by statisticians and 
underwent a series of  validation processes. Of  the 
total potential number of  patients (279,173) only 59 
(0.0002%) were lost during the process. Requests and 
plans have been made and are currently getting finalised 
to expand the database with additional data on existing 
patients and additional patients with corresponding 
data for the subsequent years, keeping the database a 
more up-to-date research tool.
For the purpose of  this study project we only used data 
of  patients who underwent their primary hip replacement 
surgery between 01/01/1999 and 31/12/2012. We 
decided to use this data to maximise the number of  
patients, improve the quality of  variables and to maintain 
an acceptable mid- to long-term follow-up period. 
During the study period 193,253 THRs were recorded 
in 164,113 patients. If  further data is released from 
the other organisations in the future, using the same 
linkage mechanism, the study period can be extended 
in the future. This would increase both the numbers of  
patients (and operations) as well as the length of  follow-
up, thereby increasing the strength of  the data (see future 
projects). 
Paper I
Data from patients who received their (total) hip 
replacement between 01/01/1999 and 31/12/2012 and 
recorded within SHAR was merged with the data from 
Statistics Sweden and the National Board of  Health and 
Welfare. In the future it is anticipated that these data will 
be merged as part of  an on-going process. The paper 
also contains a reference to the data collected on (hemi-) 
arthroplasties for hip fractures since 2005.
Paper II
The trends paper uses the research database as the 
basis for the analysis. It contains data on 193,253 
THRs in 164,113 patients (75). Patient- and surgery-
related data for this analysis have been routinely and 
prospectively collected and we used the different 
levels of  data as suggested by the international 
registry collaborations (76). We describe changes in 
the incidence and prevalence of  surgical intervention, 
changes in clinical diagnosis at intervention with the 
passage of  time, details of  comorbidity (ASA and 
Elixhauser), age at intervention (77–82), BMI, SES 
(in the form of  highest level of  achieved education) 
and surgical technique (fixation, bearing couple, 
approach). We attempted to describe the trends in 
the type of  hospital attended by patients and the day 
of  the week the surgery took place. The different 
outcomes described were: length of  stay (LOS), 
reoperation (without change of  implant, revision of  
one or more implant, short- and mid-term mortality. 
We also attempted to describe an evolution in pre- and 
postoperative PROMs using EQ-5D, EQ VAS (83), 
pain VAS and satisfaction VAS as well as Charnley 
classification (84).
Paper III
We used data from 01/01/2008 to 31/12/2012 to 
study the association between preoperative patient-
reported health status and mortality. The PROMs 
program in Sweden only reached full nationwide cover 
in 2008 (43), which was the rationale of  using only 
this 5-year cohort from the linked research database. 
42,862 patients with primary OA and complete 
preoperative PROMs were included. In the event that 
patients would have received a bilateral procedure 
during the study period, only the first performed THR 
was included. The main purpose was to study any 
association between the patient’s self-reported health 
status and postoperative mortality (Fig 4). 
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Paper IV
The data used for the relative survival was from the linked 
database and the Human Mortality Database (www.
mortality.org). Data on 131,808 patients was compared 
with birth year- and sex-matched data (spanning the 
same period) form the Human Life-table database and 
the relative survival was calculated accordingly as being 
the measured mortality versus the expected mortality. 
21,755 patients died during the study period. We only 
studied patients who received an elective primary THR 
between 01/01/1999 and 31/12/2012. Median follow-
up for survivors was 5.62 years and for study subject 
who died it was 5.43 years.
Paper V
Patients in the linked database in whom the first 
hip replacement was performed electively between 
01/01/1999 and 31/12/2012 were studied. Data on 
133,654 patients with 160,165 primary THRs and 4,719 
revisions were available. 22,070 patients deceased during 
the period. A graphical representation of  the sequence 
of  events was constructed (Fig 5).
Figure 4: Most frequent EQ-5D combinations within the study 
population 
Figure 5: Multi-state analysis possible pathway steps form first hip operation (entry) to death (absorbing state)
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Paper I
This is a pure descriptive paper on how the the databases 
were merged. We did use some descriptive statistics. Due 
to the presence of  the universal PIN, there was no need 
to use some mathematical and statistical techniques to 
check the accuracy of  the data aggregation, that are 
generally described for other data linkage studies in the 
absence of  a universal PIN.
Paper II
Continuous variables were summarized as means and 
standard deviations, categorical variables as percentages 
and absolute numbers. We used robust and non-
parametric regression for trend analyses. The outcome 
for the regression analyses was the variable of  interest 
and this was regressed on calendar year.    
Paper III
Comparison between the group of  survivors and 
deceased patients was conducted with Student’s t-test 
and χ2 test for continuous variables categorical variables 
respectively. 
The survival data was subsequently studied, summarised and 
illustrated with the help of  relative survival curves (85–87). 
This was considered a move away from the traditional 
Kaplan-Meier survival curves and Cox Proportional 
Hazards in an attempt to enable us to have better insights 
in the relation between survival of  the studied population 
compared to the general population and the differences 
between the levels of  the five EQ-5D dimensions. The 
relative survival ratio is defined as the observed survival 
in the patient group divided by the expected survival of  a 
comparable group from the general population
 SO(t )r (t ) ______
 SP(t )
where SO(t ) denotes the observed survival in the 
studied group and SP(t ) is the population or, expected 
survival (87). The population or expected survival 
was estimated from publicly available mortality tables, 
tabulated for sex and age (in years) (88).
Paper IV
Continuous variables were summarized as means and 
standard deviations, categorical variables as percentages. 
Group comparisons were provided with Student’s t-test 
and χ2-test. 
Statistical methods
Similar to the previous paper we used relative survival 
ratios (85–87), comparing the observed survival in 
the patient group divided by the expected survival of  
a comparable group (sex and age) from the general 
population
 SO(t )r (t ) ______
 SP(t )
where SO(t ) denotes the observed survival in the studied 
group and SP(t ) is the population or, expected survival 
as available from life tables (Table 3).The population 
or expected survival was estimated from publicly 
available mortality tables, tabulated for sex and age. 
Life tables have been used extensively in demography 
and demographic research and describe the extent to 
which a generation of  people (i.e. a birth year for the 
different sexes) dies off  with age and these have been 
jointly developed and maintained by the Human Life-
Table Database http://www.lifetable.de/) under the 
auspices of  the Max Planck Institute for Demographic 
Research (Germany), the Department of  Demography 
at the University of  California at Berkeley (USA) and the 
Institut national d’études démographiques (France).
Multivariable modelling proceeded with Cox 
Proportional Hazards Model in Transformed Time (89). 
Model assumptions were checked with Brownian 
bridges (90). We observed significant deviation from 
the assumption of  proportionality for the Elixhauser 
comorbidity index (ECI). We mitigated the problem 
with introducing time dependent coefficients. Graphical 
examination of  the effect of  the ECI indicated that 
there are changes in the effect measures at 5 and 8 years. 
Thus, we introduced a step function that split the data in 
3 epochs, up to 5 years, between 5 and 8 years and above 
8 years (Fig 6). The regression model then included an 
interaction term between the ECI and step function 
for time. The hazard rates for the ECI for the different 
epochs are sums of  the main and interaction terms. 
Paper V
We used the principles of  the multi-state (MS) analysis, 
as described by Putter and Willekens and the R software 
package (91, 92). MS models are used to describe life 
histories or the process where subjects move from one 
state to another state, as there are multiple endpoints 
within the study period in the case of  long-term 
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Table 3.  Lifetable from Sweden for patients born in 1935  
and at different ages for the two different sexes  
(adapted from Human Life-table Database)
birthyear age Probability of death Residual life left Probability of death Residual life left
female male
1935 55 0.00945 21.08 0.01238 20.24
1935 56 0.01052 20.28 0.01266 19.49
1935 57 0.01184 19.49 0.01460 18.73
1935 58 0.01270 18.71 0.01457 18.00
1935 59 0.01430 17.95 0.01756 17.26
1935 60 0.01434 17.20 0.01758 16.55
1935 61 0.01687 16.44 0.02019 15.84
1935 62 0.01753 15.71 0.02046 15.15
1935 63 0.02081 14.98 0.02113 14.45
1935 64 0.02323 14.28 0.02617 13.75
1935 65 0.02479 13.61 0.02731 13.10
1935 66 0.02403 12.94 0.02948 12.45
1935 67 0.03025 12.24 0.03584 11.81
1935 68 0.03359 11.60 0.03774 11.22
1935 69 0.03863 10.98 0.04315 10.63
1935 70 0.03796 10.39 0.04489 10.08
1935 71 0.04747 9.78 0.04621 9.52
1935 72 0.05289 9.23 0.05514 8.95
1935 73 0.05419 8.70 0.05996 8.43
1935 74 0.06452 8.16 0.06628 7.92
1935 75 0.07064 7.67 0.07643 7.43
1935 76 0.08083 7.19 0.08370 6.98
1935 77 0.08893 6.76 0.09561 6.54
1935 78 0.09356 6.34 0.09796 6.15
1935 79 0.10967 5.91 0.10421 5.73
1935 80 0.11853 5.54 0.12708 5.31
1935 81 0.12816 5.18 0.14142 4.96
1935 82 0.14413 4.82 0.14124 4.64
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follow-up. It describes the hip-related timeline between 
operations, revisions and mortality. We adopted a MS 
model describing this pathway of  patients between 
a series of  discrete states in a continuous time. This 
disease progression model had five states and described 
the pathway of  a patient from the 1st THR onwards 
(Fig 4). The patients entered the study at the time of  
the 1st THR surgery (State 1). The patient can remain 
in state 1 or subsequently advance into further states. If  
the patient dies, he or she will move into the end-state 
5 (the absorbing state of  death)(Fig 7). Probabilities 
and hazard ratios with a 95% CI were calculated for the 
different states and the transitions.
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Fig 6: Graphical representation of  
the evolution of  the hazard ratio of  
the Elixhauser comorbidity index 
as a function of  time.
Fig 7: Venn diagram providing information on the state prior 
to the absorbing state. (First THR=first performed THR; 
Contralateral THR=subsequent performed THR; First THR 
REV= Revision of  the first performed THR; Contralateral 
THR REV=revision of  subsequent performed THR)
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Paper I
Linking Swedish health data registers 
to establish a research database and 
a shared decision-making tool in hip 
replacement
Data were structured by statisticians and underwent 
a series of  validation processes. Of  the total potential 
number of  patients (279,173) only 59 (0.0002%) were 
lost during the process.
This database is the starting point of  several research 
projects identifying factors that influence the outcome 
of  hip arthroplasty. Socio-economic factors, primary 
diagnosis and comorbidities affect the outcomes and a 
clinical validated instrument to help the decision-making 
between the patient and healthcare providers could well 
be developed as a result of  the identification of  risk 
factors, based on a review of  a large dataset (Table 4). 
Summary of results
Paper II
Trends in the Patient Demographics, 
Socio-Economic Characteristics, Sur-
gical Factors and Outcomes between 
1999–2012
In the majority of  our study population the main indication 
for the surgery patients was primary osteoarthritis (OA) 
and the proportion of  patients with this diagnosis 
increased further during the period at the expense 
of  decreasing number of  patients with inflammatory 
arthritis and hip fracture (Fig 8). Comorbidity and ASA 
scores increased for each year (Fig 9). The share of  all 
cemented implants has dropped from 92% to 68% with 
a corresponding increase of  all uncemented components 
from 2% to 16% (Fig 10). The biggest increase is in the 
age range 61–70 years group (Fig 11). More than 88% of  
the bearings were metal-on-polyethylene. Length of  stay 
decreased by about 50% to 4.5 days in 2012 (Fig 12). The 
Table 4.  Example of available demographics, patient-related, surgery-related and  
socioeconomic data within the study database. Variables available within the  
different database and accessible within the linked research database (not exclusive).
Variable category Variables
Swedish Hip Arthroplasy Register
Demographics age, gender, weight, height
Diagnosis & comorbidities ICD-10 code for hip pathology, laterality, ASA classification, self-reported Charnley  classification
Date of surgery date of primary surgery &reoperation
Hospital type hospital identifier & administrative category
Type of surgery Primary/reoperatin/revision, THR/hemi-arthroplasty, implant characteristics/surgical approach
PROMS
preoperative EQ-5D, EQ VAS, pain VAS
postoperative  EQ-5D, EQ VAS, pain VAS, satisfaction VAS
postoperative @ 1, 6, 10 years
Preop treatment physiotherapy & education
National Board of Health and Welfare
Demographics cause and date of death
Diagnosis & comorbidities comorbidities, Elixhauser, Charlson, data from drug and cancer register
Date of surgery admission & discharge day, administrative category outpatient & inpatient
Hospital type hospital identifier & administrative category outpatient & inpatient
Statistics Sweden
Demographics
place of birth, residency, relocation, marital status, income, family circumstances, education, 
benefits
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30-day mortality rate dropped from 0.5% to 0.4% and the 
90-day mortality from 1.1% to 0.7% (Fig 13). Re-operation 
rate at 30 days, 90 days and 2 years decreased from 1.7% 
to 1.0%, 2.2 to 1.3% and 8.5 to 2.2% respectively (Fig 14). 
Revisions within the same time frames decreased from 1.7 
to 1.0%, 2.2 to 1.3% and 3.3 to 2.0% (2010) respectively 
(Fig 15). The postoperative PROMs improved despite 
the preoperative pain scores getting worse (Fig 16–17). 
We can conclude that in Sweden, the demographics of  
the patients, the comorbidities and the primary diagnosis 
for surgery are changing. With regards changes in clinical 
practices surrounding hip replacement, Sweden has 
always been considered to be a very conservative country. 
Some changes have taken place, however, but it is unclear 
whether the recorded changes in practice have had any 
influence (positive or negative) to the outcomes such as 
mortality, re-operations, revisions and PROMs which 
have each improved during the review period.
Figure 8: Trends in numbers of  primary THR performed and 
trends in clinical diagnosis at the time of  primary THR in 
 Sweden between 1999–2012 (adapted from Cnudde et al (75))
Figure 9: Trends in Elixhauser comorbidity index (A) and ASA 
score (B) collected preoperatively at the time of  the  primary THR 
during study period (adapted from Cnudde et al (75))
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Figure 10: Trends in method of  fixation for primary THR during 
study period (adapted from Cnudde et al (75))
Figure 12: Trends in length of  stay for primary THR in Sweden 
between 1999–2012 (adapted from Cnudde et al (75))
Figure 13: Trends in 30-& 90-day mortality after primary THR 
(adapted from Cnudde et al (75))
Figure 11: Age range trends of  primary THR in Sweden between 
1999–2012 (adapted from Cnudde et al (75))
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Figure 16: trends in preoperative PROMs prior to primary THR 
(adapted from Cnudde et al (75))
Figure 17: trends in postoperative PROMs following primary THR 
(adapted from Cnudde et al (75))
Figure 14: Re-operation trends in the first 30 days, 90 days and 2 
years following primary THR (adapted from Cnudde et al (75))
Figure 15: Revision trends in the first 30 days, 90 days and 2 years 
following primary THR (adapted from Cnudde et al (75))
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Paper III
Pre-operative patient-reported health 
status influences mortality after total 
hip replacement 
During the study period 1,346 patients out of  the 42,862 
died (follow-up range 5.0 years, mean 2.4 years, SD 
1.4 years). Statistically significant differences between 
survivors and deceased regarding sex, age at day of  
operation, hospital type, the five EQ-5D dimensions, 
the EQ VAS, the pain VAS and educational level were 
identified and are represented in Table 5. 
Table 5.  Patient demographics and pre-operative health related quality of life of the cohort.  
The data is summarized as absolute numbers and percentages for discrete variables and means  
and standard deviations for continuous variables (adapted from Cnudde et al. (116)).
Alive Dead
n =41 516 n=1 346
Mobility (%) No problems 3 210  (7.7) 52  (3.9)
Moderate problems 38 190  (92.0) 1 279  (95.0)
Severe problems 116  (0.3) 15  (1.1)
Self-care (%) No problems 32 066  (77.2) 910  (67.6)
Moderate problems 9 102  (21.9) 403  (29.9)
Severe problems 348  (0.8) 33  (2.5)
Usual activities (%) No problems 16 086  (38.7) 460  (34.2)
Moderate problems 21 125  (50.9) 684  (50.8)
Severe problems 4 305  (10.4) 202  (15.0)
Pain/discomfort (%) No problems 631  (1.5) 16  (1.2)
Moderate problems 23 822  (57.4) 706  (52.5)
Severe problems 17 063  (41.1) 624  (46.4)
Anxiety/depression (%) No problems 23 963  (57.7) 711  (52.8)
Moderate problems 16 079  (38.7) 568  (42.2)
Severe problems 1 474  (3.6) 67  (5.0)
EQ VAS score (sd) 54.77  (22.17) 50.61  (21.76)
Pain VAS score (sd) 62.39  (15.91) 62.67  (17.34)
Females (%) 23 358  (56.3) 633  (47.0)
Age (sd) 67.70  (10.09) 75.76  (8.83)
Educational level (%) Low 14 018  (33.8) 658  (48.9)
Middle 17 038  (41.0) 466  (34.6)
High 10 460  (25.2) 222  (16.5)
Hospital (%) University 3018  (7.3) 117  (8.7)
County 13 026  (31.4) 464  (34.5)
Rural 17 490  (42.1) 603  (44.8)
Private 7 982  (19.2) 162  (12.0)
The investigated cohort of  patients, who underwent 
a THR for primary OA had a better survival than the 
predicted survival of  the general population (Fig 18). 
Males had worse survival than females and it was 
obvious from the analysis that the ‘protective effect of  
hip replacement on mortality’ was more profound in the 
more advanced age group (Table 5). 
Broken down by the five EQ-5D dimensions, we 
observed differentiated survival patterns (Fig 19). 
Patients who reported no problems on any of  the EQ-
5D dimensions had better survival than the general 
population and patients who reported moderate or 
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Figure 18: The relative survival of  the cohort during the studyperiod 
(adapted from Cnudde et al (116)).
Figure 19: Relative survival by dimension of  EQ-5D. The red line 
represents patients who report no problems, the blue line moderate 
problems and the green line severe problems preoperatively in each of  
the dimensions (adapted from Cnudde et al (116)).
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Table 6.  Results of the relative survival regression analysis on mortality after  
total hip replacement. The results are presented as Hazard Rates (HR) and associated  
95 % confidence intervals (adapted from Cnudde et al. (116)). 
Hazard Rates 95 % CI
Mobility No problems ref
Moderate problems 1.46 1.09–1.96 
Severe problems 2.65 1.43–4.92
Self-care No problems ref
Moderate problems 1.15 1.01–1.31
Severe problems 1.57 1.08–2.29
Usual activity No problems ref
Moderate problems 1.05 0.93–1.20
Severe problems 1.28 1.06–1.56
Pain/discomfort No problems ref
Moderate problems 1.07 0.64–1.77
Severe problems 1.20 0.71–2.00
Anxiety/depression No problems ref
Moderate problems 1.09 0.96–1.22
Severe problems 1.24 0.95–1.62
EQ VAS (in units of 10) 0.95 0.92–0.98
Pain VAS (in units of 10) 0.96 0.92–1.01
Sex: Male ref
Female 0.86 0.76–0.96
Age: 0.96 0.95–0.97
Operation Year: 0.91 0.86–0.96
Education: Low ref
Middle 0.93 0.83–1.06
High 0.85 0.73–1.01
Hospital: University ref
County 0.79 0.65–0.97
Rural 0.81 0.67–0.99
Private 0.72 0.56–0.91
severe problems. Patients who reported moderate 
problems on any of  the EQ-5D dimensions had better 
survival than the general population and patients 
who reported severe problems. The worse the patient 
scored on any of  the EQ-5D dimensions the higher 
the hazard rates of  increased mortality became. Only 
a relatively small number of  patients (131) reported 
severe problems on the mobility dimension but they 
were found to have worse survival than the general 
population. Patients who reported severe problems on 
the self-care dimension had a slight drop in survival 
probability straight after the operation. In the time span 
between one to four years after the operation these 
patients had better survival than the general population; 
after year four the survival chances worsened. Patients 
who reported severe problems on the dimensions pain/
discomfort, usual activities and anxiety/depression had 
better survival than the general population. This pattern 
was reinforced by the multivariable regression analysis 
(Table 6).
LONGITUDINAL OUTCOMES FOLLOWING TOTAL HIP REPLACEMENT
36
Reviewing the EQ VAS data we also discovered an 
association between decreased survival and a lower 
patient-reported overall health. The pain VAS was 
neither clinically nor statistically significantly associated 
with a difference in survival.
We identified a trend towards better survival after 
THR with higher obtained educational level, but this 
observation did not reach statistical significance. In 
addition to the results in the published paper an analysis 
per EQ-5D profile was performed for the seven most 
frequent profiles and is presented in figure 20.
Paper IV
Relative survival following elective 
total hip replacement in Sweden
Between 1999 and 2012 a total of  131,808 patients 
underwent elective hip replacement. By the end of  
the follow-up period (31/12/1012) 21,755 had died. 
There were significant differences for most covariates 
considered between survivors and deceased patients and 
these are represented in Table 6. The maximum follow 
up period was up to 14 years.
In 91% of  the study population the indication for hip 
replacement surgery was primary osteoarthritis (Table 7).
Patients with primary osteoarthritis had better survival 
than a matched population through the whole follow 
up period (Fig 21). Patients in whom the main diagnosis 
for surgery was a sequelae of  childhood hip disorder 
had similar survival rate as a matched population. 
Patients operated because of  avascular necrosis of  the 
femoral head, inflammatory joint disease or secondary 
osteoarthritis following hip related trauma had a lower 
survival rate than a matched population. These three 
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Figure 20: Relative survival for the seven most frequently observed 
EQ-5D profiles. 
diagnoses had a significantly lower survival than patients 
with primary osteoarthritis, while no statistically significant 
difference was detected between sequelae childhood hip 
disorder and primary osteoarthritis (Fig 22). 
Females had generally better survival than males. Patients 
operated at more advanced ages had significantly 
better survival than their peers of  the same age from 
the general population. Being single or widow and 
having completed only lower levels of  education were 
associated with lower survival rate. Comorbidities had 
a negative effect on survival. The year of  operation 
was positively associated with survival rate. Crude and 
adjusted hazard ratios for the diagnosis, surgical factors, 
comorbidities, and SES are represented in Table 8.
The mortality after use of  all cementless fixation 
differed from the other types of  fixation (i.e., fully 
cemented, reversed hybrid and hybrid fixation), but the 
results differed depending on type of  analysis employed. 
Uncemented THR tended to be associated with better 
survival with a different outcome between the Cox 
regression analysis, the relative survival rate and the 
Kaplan-Meier survival analysis (Fig 23).
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Table 7.  Demographics of the whole cohort, the surviving cohort, and the deceased cohort  
during study period 1999–2012 (adapted from CORR)
Demographics Alive Dead 
Number 110,053 21,755
Sex = female (%) 64,228  (58) 11,807  (54) 
Age (mean [SD]) 66.77  (10) 75.19  (8)
Education (%)    
Low 42,147  (38) 12,591  (58) 
Middle 43,330  (39) 6598  (30) 
High 24,576  (22) 2566  (12) 
Civil status (%)    
Couple 63,884  (58) 10,588  (49) 
Single 29,471  (27) 4596  (21) 
Widow 16,698  (15) 6571  (30) 
Diagnosis (%)    
Primary osteoarthritis 10,1267  (92) 19,410  (89) 
Inflammatory joint disease 2500  (2) 733  (3) 
Sequelae of a childhood hip disorder 2811  (3) 191  (1) 
Femoral head necrosis 3319  (3) 1318  (6) 
Secondary osteoarthritis 156  (0) 103  (0) 
Fixation (%)    
Cemented 83,644  (76) 20,698  (95) 
Uncemented 13,513  (12) 361  (2) 
Hybrid 3083  (3) 364  (2) 
Reversed hybrid 9813  (9) 332  (2) 
Elixhauser index (mean [SD]) 0.57  (1) 0.73  (1)
Elixhauser index tabulated (%)    
0 69,777  (63) 12,742  (59) 
1 25,094  (23) 4854  (22) 
2 10,144  (9) 2469  (11) 
3 5038  (5) 1690  (8) 
Year of operation (mean [SD]) 2006.54  (4) 2002.72  (3)
Follow-up (mean [SD]) 5.96  (4) 5.64  (3)
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Figure 21: Relative survival curve for the complete study population 
(adapted from Cnudde et al. in CORR)
Figure 23 A&B:   
A. Relative survival curve of  the cemented versus the uncemented group with inset detailed analysis of  the first 90 days postoperatively 
B. Kaplan-Meier survival analysis of  the same cohort
Figure 22: Relative survival curve for the study population per 
diagnostic indication for surgical intervention with CI (adapted from 
Cnudde et al. in CORR)
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Table 8.  Crude and adjusted hazard ratios for different variables; hip-related clinical diagnosis at the 
time of surgery, patient-related, surgery-related factors and SES (adapted from CORR)
Adjusted
Studied variables HR 95% CI HR 95% CI
Diagnosis
Primary osteoarthritis Reference
Inflammatory joint disease 2.21 2.05–2.38 1.49 1.38–1.61
Sequelae of a childhood hip disorder 1.25 1.09–1.45 1.02 0.88–1.18
Femoral head necrosis 1.68 1.59–1.78 1.69 1.60–1.79
Secondary osteoarthritis 2.35 1.93–2.85 2.46 2.03–2.99
Sex
Male Reference
Female 0.93 0.90–0.95 0.97 0.94–1.00
Age 0.96 0.96–0.97 0.96 0.96–0.96
Civil status
Couple Reference
Single 1.35 1.30–1.40 1.33 1.28–1.38
Widow 0.98 0.95–1.02 1.14 1.10–1.17
Education
Low Reference
Middle 0.94 0.91–0.97 0.90 0.87–0.93
High 0.79 0.76–0.83 0.76 0.73–0.80
Fixation 
Cemented Reference
Uncemented 1.00 0.90–1.11 0.78 0.70–0.87
Hybrid 1.27 1.15–1.41 0.93 0.83–1.03
Reversed hybrid 0.96 0.86–1.07 0.93 0.83–1.04
Year of operation 0.95 0.95–0.95 0.95 0.95–0.96
Elixhauser up to 5 years
0 Reference
1 1.37 1.31–1.44 1.49 1.42–1.57
2 1.79 1.69–1.90 2.07 1.95–2.20
3+ 2.76 2.59–2.94 3.32 3.11–3.55
Elixhauser between 5 and 8 years
0 Reference
1 2.20 1.99–2.43 1.52 1.36–1.68
2 2.76 2.42–3.15 1.96 1.72–2.25
3+ 3.67 3.13–4.30 2.63 2.23–3.10
Elixhauser over 8 years
0 Reference
1 2.62 2.36–2.92 1.33 1.18–1.49
2 3.32 2.86–3.85 1.74 1.48–2.04
3+ 4.47 3.67–5.45 2.40 1.95–2.94
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Table 9.  Patient demographics  
of complete study group
n 133654
Age (mean (sd)) 67.99  (10.87)
Sex (%)
Male 57058  (42.7)
Female 76596  (57.3)
Diagnosis
Primary osteoarthritis 122568  (91.7)
Inflammatory joint disease 3199  (2.4)
Sequel childhood hip disorder 3148  (2.4)
Femoral head necrosis 4735  (3.5)
Elixhauser Index (mean (sd)) 0.61  (0.96)
Surgical approach 
Lateral 59355  (44.4)
Posterior 74299  (55.6)
Fixation (%)
Cemented 104560  (78.2)
Uncemented 13500  (10.1)
Hybrid 3336  (2.5)
Reversed Hybrid 9981  (7.5)
Resurfacing 1666  (1.2)
Clinic type (%)
University 14080  (10.5)
County 44897  (33.6)
Rural 55126  (41.2)
Private 19551  (14.6)
Paper V
Risk of further surgery on the same or 
opposite site or mortality after primary 
total hip arthroplasty. A multi-state 
analysis of 133,654 patients from the 
Swedish Hip Arthroplasty Register
The median follow-up time from the first and from the 
second THR until death or censoring (emigration) was 
respectively 5.56 years (95 % CI: 5.52–5.59) and 4.17 
years (95 % CI: 4.12–4.21). Patient demographics are 
described in table 9.
We identified that transition probabilities and the 
probability of  staying in a state were highly time 
dependent (Fig 24). Patients were twice as likely 
(transition ratio = 2.13, 95 % CI 2.07–2.19) to have 
their other hip replaced than to die during the study 
period. However, towards the end point of  the study, 
probabilities were converging. A contralateral primary 
hip replacement was 7.5 times (95 % CI 7.31–7.89) 
more likely than revision of  the first hip. A hip-related 
time line is represented in figure 25.
We calculated hazard ratios for the most frequent 
transitions. We identified influence of  sex, indication 
for arthroplasty of  the first hip, comorbidity, surgical 
approach, implant fixation, and highest level of  
obtained education as variables influencing transition. 
The influences on transitions are represented as graphs, 
tables and Forrest plots.
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Figure 24: Multi-state analysis with transition probabilities at different times point following the first hip replacement
Figure 25: State occupation probabilities at different points in time 
during study period
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Strengths
The studies are based on existing data of  the research 
database of  the SHAR and the administrative databases 
of  the SCB and Socialstyrelsen. This has minimized time 
and the costs for this project. The sample size is sufficient 
large, containing almost all elective hip replacements 
performed during the study period as part of  the 
nationwide collection of  information on THR within the 
SHAR. The quality of  observational studies depends on 
quality and validity, reliability, coverage and completeness 
of  the data. The SHAR is a well-established, nationwide, 
prospective observational hip arthroplasty register. 
We are aware that the coverage (100%), completeness 
(98.6%) and validity of  the SHAR data is extremely 
high and has been so during its existence (42). The 
population registers should cover migration and it is a 
requirement by law that people who move abroad for 
more than a year (intentional or effective) should be de-
registered (93). The SHAR data has been prospectively 
and independently collected by the local surgeons and 
hospital teams and this data has then subsequently gone 
through a rigorous process of  quality control with up to 
6 different steps (table 1). The history and longevity of  
Strengths, limitations and bias
the SHAR makes it possible to study long-term trends 
and allows us to pick-up infrequent complications like 
early mortality. Using the amalgamation of  the data 
sources into a single research database allows us to adjust 
for some confounders such as SES, comorbidity and 
potentially study readmissions and subsequent episodes 
of  hospital care resulting from adverse events. For some 
purposes registry-based studies are more useful than 
traditional RCT’s and the influence of  the registers on the 
evolution of  practices that improve the quality of  clinical 
care and their contribution to value-based medicine is 
now considered as being reflective of  real-life practice. 
For ethical reasons, the research question of  the 
third paper can only be answered using observational 
data. In order to answer the research question there 
need to be a sufficient number of  “observations” to 
provide statistically robust evidence for whether, or 
not, associations exist. Besides using the STROBE 
(strengthening the reporting of  observational studies 
in epidemiology) statement, we used the guidelines for 
reporting ‘big data’ as suggested by Costa et al. and were 
able to describe the nature of  datasets, the variables and 
the significance of  the results (Table 10) (94, 95).
Table 10.  BJJ big data interim reporting guidelines and current research
Bone and Joint Journal Big Data Interim Reporting Guidelines
Methods Results
datasets variables significance
purpose data quality denominators linkage code list validation
Paper I National audit 
programme
99%  
see annual 
reports
Countrywide  
Swedish Population 
undergoing THR
V in methods V not applicable
Paper II National audit 
programme
99%  
see annual 
reports
Countrywide  
Swedish Population 
undergoing THR
V in methods V p<0.05  
clinical significance=v
Paper III National audit 
programme
99% s 
ee annual 
reports
Countrywide  
Swedish Population 
undergoing THR
V in methods V p<0.05  
clinical significance=v
Paper IV National audit 
programme
99%  
see annual 
reports
Countrywide  
Swedish Population 
undergoing THR
V in methods V p<0.05 c 
linical significance=v
Paper V National audit 
programme
99%  
see annual 
reports
Countrywide  
Swedish Population 
undergoing THR
V in methods V p<0.05  
clinical significance=v
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Limitations
Whereas the independence of  data collectors can be seen 
as an advantage and a form of  objectivity, the diligence 
applied to produce accurate coding will vary between the 
different systems. The quality of  the data can however be 
subjected to a 6-step verification process.
It will be unavoidable that there will be some missing 
data: some citizens fail to deregister and it is estimated 
that there is an over-coverage of  0.1% for Nordic 
citizens, but this might well be higher for other 
groups (93). Further analysis of  the official data shows 
that emigration of  Scandinavian residents out of  
Sweden is extremely low and previous work from the 
register has revealed that the uptake of  arthroplasty in 
the migrant population is extremely low. In common 
with other Western European countries with accessible 
health services there is the possibility of  health tourism 
and this cannot be accounted for. We are aware that a 
number of  revisions will not be recorded and this has 
been described in previous work. Reoperations for 
infections as well as open reduction and internal fixation 
of  periprosthetic fractures are not routinely recorded in 
most registers and studies of  the SHAR have confirmed 
poor reporting of  these procedures (96, 97). Lindgren 
et al. validated reoperations for infections using a 
combination of  patient records, the Swedish Drug 
Prescription Register (SDPR) and found a completeness 
of  67% of  the reoperations for infection (96). It is 
likely that with the updated guidelines and principles 
of  debridement, antibiotics and implant retention 
(DAIR) with exchange of  femoral heads and liners, 
the recording of  implant infection has become more 
accurate. Chatziagorou et al. performed a linkage study 
between the SHAR data and the NPR and were able 
to demonstrate that 32% of  the periprosthetic fractures 
have not been recorded in the SHAR (98). In the case of  
revisions or failures for infection, patients might not have 
had operations; they may remain under observation on 
long-term suppression therapy. In addition episodes of  
surgery might not be recorded or patients may undergo 
a surgical procedure without exchange of  implants with 
no record of  the intervention. 
Our studies have purposely excluded patients with 
simultaneous bilateral procedures, Although bilateral 
operation are infrequently undertaken within Sweden, 
the results may be influenced by eliminating these cases 
from the study population. There is an evolution in 
minimum data set requirements within registers with the 
passage of  time (42). Some of  the data, now routinely 
collected, such as BMI and ASA grade was not available 
in earlier sets of  registry data. Using cross-tabulation we 
have encounters a few cases of  revisions where the data 
recorded pathways that were not possible. A few of  the 
PIN’s might have been re-assigned and have led to some 
erratic results. Cases were removed from the analysis 
where nonsensical results were identified (for example 
dying prior to revision). 
In the case of  register studies there is a theoretical risk 
of  data mining. This analysis has been performed using 
well-defined and rigorous study questions/hypotheses 
and data mining (or dredging) was avoided. When 
analyses delivered findings of  statistical significance 
but doubtful clinical relevance these findings are clearly 
discussed. Throughout the study results were interpreted 
by practicing clinicians.
The length of  follow-up is clearly important when 
interpreting the data. Interventions are taking place at 
a younger age and with increasing life expectancy the 
time-in-situ of  the implant is increasing exposing the 
implant to an increased potential from complications. 
The life-time risk for revision might well have to be 
adapted and the strength of  evidence might only be valid 
on the implants and techniques studied (99). Outcomes 
are associated with the implants and technologies that 
were used at the time point of  the intervention and 
many changes have taken place with the passage of  time 
such as the introduction of  highly cross-linked poly-
ethylene, the routine use of  bigger femoral heads, small 
changes in implant geometry and extension of  the range 
of  implants assuming equivalence of  outcome with the 
newer prostheses. 
For socio-economic status we are aware that multiple 
variables can be identified as determining the SES. 
Examples are household and individual income as well 
as education level and occupation. The database records 
many of  these variables but based on previous work 
the decision was made to use highest level of  recorded 
educational achievement, categorized in 3 levels, as a 
marker for SES. It is possible that the influence of  SES 
on outcome might not be comprehensively described as 
a result of  this decision (100–102).
Bias and register-based research
Bias has been described as deviation from the truth/any 
factor that tends to deviate the results or the conclusions 
of  study systematically away from the truth. Bozic et 
al state in their “Orthopaedic Healthcare worldwide” 
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column that any form of  bias that leads to erroneous 
conclusions must always be taken into account whatever 
the size of  the data (65). I used some background reading 
on bias and register studies to identify and explain some 
potential sources of  bias related to register studies 
(Table 11) that may apply to the studies in these papers 
are discussed (103–106)(http://methods.cochrane.org/
bias/assessing-risk-bias-included-studies).
Selection bias
Bias may be caused by analysing a study population 
that is different and not representative of  the overall 
population. The chance of  selection bias within cohort 
studies is small but exists. Whilst selection bias is reported 
to be less of  a problem in register type studies based on a 
national surveillance program, it is well known that some 
patients will not be offered arthroplasty surgery because 
of  medical comorbidities. Such a selection process is 
unavoidable and even in a well-designed RCT this group 
of  patients will be excluded and subject to allocation bias. 
The patient’s idea of  success does not always correlate 
with what the surgeon believes is a good outcome. Not all 
implants that fail on clinical or radiological criteria go on 
to a revision procedure. Some patients will not be willing 
to go through a further intervention. On occasion the 
surgeon may advise that the risk/benefit ratio is not in 
favour of  revision surgery on the grounds of  complexity 
or patient-related factors. Outcomes in the private sector 
are likely to be influenced by cherry-picking. 
It needs to be understood that the selection process 
in offering revision surgery is usually based on a 
multidisciplinary discussion between different health-
care professionals. With an extremely high rate of  case 
follow-up and data completeness selection bias should 
not be considered an issue.
Performance bias
Performance bias results from differences that may 
occur in the quality of  care provided to the participants 
in the study. The design of  register-based research 
largely avoids performance bias as there is unlikely 
to be a systematic allocation of  better surgical skilled 
surgeons for one group, compared to another. We 
are unable to assess the differences in quality of  care 
provided by the different providers. However, we are 
confident that the quality of  the care in the different 
hospitals is comparable, as can be seen in the clinical 
value compasses of  the different hospitals. The implant 
selection will, however, be based on personal preference. 
Blinding is impossible in register-based studies, all 
patients have received the studied intervention. There 
will be a difference in quality of  care provided between 
surgeons, hospitals and regions. As the data is collected 
prospectively and nationwide, the data should be a true 
reflection of  the real world.
Detection bias
There is the potential for artifact in studies, which 
can result from the use of  poorly validated outcome 
measures, not collecting the data correctly or under 
diagnosing adverse outcomes. The outcomes applied 
in these studies are well-validated and objective 
measurements of  the results of  treatments. There are 
potential issues with coding and that is inherent in the 
system. With regards to comorbidity, individuals who 
have no contacts with healthcare would score 0 on the 
Table 11.  Types of bias in register-based research
Bias Risk in register-based studies How to avoid
Selection bias minimal nationwide collection
Performance bias minimal all surgeons/all hospitals
Detection bias existing combination SHAR/NPR 
Validated outcome measures
Attrition bias minimal Limit loss to follow-up 
minimize missing data 
Analysis of excluded patients/flowcharts
Reporting bias existing research plan 
no data mining
Other Bias 
Misclassification existing unavoidable to a certain extent
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comorbidity indices, but are they really healthy? A review 
of  the patients was undertaken, studying the difference 
in survival between patients with and without hospital 
visits prior to THR and we found that people without 
recorded hospital visits during the year preceding the 
intervention had a better survival than the patients who 
had a contact with the secondary care but scored 0. As 
already mentioned earlier some mortality and revisions 
for infection/periprosthetic fractures might not be 
recorded in case of  emigration.
Attrition bias
If  there is a loss of  participants, attrition bias occurs as 
the results in subjects that did not run to completion are 
discounted. Given the nationwide set up of  the SHAR 
and the strong linkage that can be made with other 
governmental organizations, we are sure we are able to 
track the Swedish population thereby accurately describe 
the longitudinal outcome. There are no systematic 
differences in the patients included or excluded from 
the studies. We have on several occasions studied the 
outcomes of  patients that were omitted as part of  
missing data. Flowcharts were used to clearly identify 
patient groups that were not studied. Patients who are 
not returning PROMs questionnaires might be poorly 
performing and this subgroup has been studied before.
Reporting bias
Bias may be caused by intentionally and selectively 
revealing or suppressing information. We have 
attempted to avoid this as all the studied material and 
the research questions have been answered whether or 
not the findings reveal statistical or clinical significance. 
Other bias
Misclassification bias is something that could well be 
possible as the difference between primary and sequelae 
of  childhood diseases is not always clear cut (107).
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The general public and patients expect the medical 
profession to uphold standards in healthcare, originally 
described in the ‘Oath of  Hippocrates’ and subsequently 
adapted in different legislations and guidance from 
national medical councils. As practitioners of  the ‘art 
of  medicine’, it is adamant that the “primum non nocere” 
principle is central in all our activities, whether it is 
clinical practice, research or our day-to-day life. The 
declaration of  Helsinki, developed and updated regularly 
by the World Medical Association (WMA) has reiterated 
this necessity of  the “first do no harm” principle (108).
There is near universal acceptance in Scandinavia of  the 
need for research and development in healthcare. Good 
epidemiological research in Sweden and the Nordic 
countries is facilitated by the way healthcare is organised 
and delivered for its population and by the structure of  
the nationwide registries. This is further enhanced by the 
trust of  the population in research and development, the 
universal acceptance and overarching social equality. Of  
fundamental importance in identifying and tracking the 
population is the adaptation of  an unique and universal 
personal identifier (109). Using the Personal Identity 
Number (PIN) the databases were merged providing 
a combination of  both surgical-specific data, general 
medical data consisting of  previous medical history and 
postoperative surgical events, contacts with healthcare 
providers, medication usage and socio-economic 
data (74). The data is safely stored on encrypted servers 
and the PIN has been removed and replaced by a unique 
identifier without any connection to the PIN (Fig 3)(109). 
Data is thereby “pseudonymised” and the unwarranted 
re-identification of  data prevented. This research 
project, based and reliant on the merger of  the databases 
of  the SHAR, Statistics Sweden and the National Board 
for Health and Welfare, has been and will be subjected 
to the legislation and ethical principles of  Sweden, the 
European Union and the WMA (64). The potential 
harm to the individual patient is, as a result, minimized 
as researchers are unable to identify individual patients 
because the unique personal identifiers (PIN) have been 
replaced by different identifiers (a number between 1 
and infinity) and the PIN’s are not in the possession of  
the research team. This makes the research compliant 
with the ethical principles for medical research involving 
human subjects (WMA) and the Swedish Personal Data 
Act (1998) and Swedish Patient Data Law (2009). Besides 
Ethical Considerations
all the above efforts there are further clear warnings to 
make sure that patients’ privacy as well as their health 
information should be protected and respected (65). 
Register-based research does not need written consent 
from participants. For reasons of  public interest both 
the EU (EU directive on Data Protection 95/46) as well 
as the Swedish Legislation allow the use of  personal 
data for research purposes to be used with consent from 
the participating individual, if  it has been obtained or 
without consent if  the data is processed anonymously 
or in a key–coded form. Getting consent for data-
collection and its subsequent use in scientific research 
would be practically infeasible and uneconomical. This 
deviation from the informed consent regulation is based 
on the judgment that doing good, justice and solidarity 
outweigh the risks of  harm and autonomy (35). Also 
in accordance to the Swedish Patient Act (2008:355) 
patients receive information about being registered and 
have a full right to opt out. During the 35 years history 
of  SHAR, few patients have applied to see their data and 
only two have decided to opt-out. The linking process 
and the current project was granted ethical approval 
from the medical division of  the regional ethical 
committee in Gothenburg under the Dnr 271-14.
In 2014 Benson et al described the ethical standards 
we, as orthopaedic surgeons, should adhere to and 
stated that treatment should be offered on the best 
available evidence (110). Whereas there have been great 
advances in the past, the introduction of  some newer 
implants and some modifications to clinical practice and 
have not resulted in an improved outcome, but have 
actually caused patients harm and have blemished the 
orthopaedic profession (111). Deeper analysis could well 
expose a lack of  ethical principles and scientific evidence 
in the development of  the newer technologies (112, 
113). In absence of  well-enough designed and powered 
RCT’s in orthopaedics, register studies have been 
considered an extremely valid alternative (52, 55, 60, 
112, 114). The proven benefits for the patients are 
an improved healthcare and a reduction in potential 
harm. As a consequence, many Western countries have 
subsequently endorsed joint replacement registers (72, 
115). The relative low revision rate of  THRs in Sweden 
(compared to USA/UK/Australia) has been attributed 
partially to a well-functioning and validated SHAR, with 
LONGITUDINAL OUTCOMES FOLLOWING TOTAL HIP REPLACEMENT
48
engagement of  the population, clinicians, the decision-
makers and the Swedish Orthopaedic Association. 
The effect of  preoperative self-reported health on 
mortality could in theory lead to an ethical dilemma. The 
association between decreased preoperative mobility 
and self-care and higher postoperative mortality may 
make healthcare professionals reconsider the value 
of  the procedure in this patient population (116). In 
this case, the evidence is based on an observational 
study using registry data. However, the set-up of  an 
appropriately powered RCT to confirm the findings 
of  this analysis would in my view be unethical. The 
intervention, whilst it has a risk to life, should be 
offered to a patient in a joint decision-making process 
allowing the possibility to deliver a reduction of  pain, 
improved mobility and thereby an improvement in the 
quality of  life. The increased mortality risk is certainly 
something the surgical teams will have to discuss prior 
to the surgery, so the patient can make a well-informed 
and balanced decision. The paper on the association 
between preoperative patient-reported health status 
and mortality after THR should in no way be used to 
deter surgeons providing patients with a life-changing 
operation, but has to be used to assess and discuss risks 
at an individual patient level as part of  an informed, 
joint decision-making process (116).
The operation of  total hip replacement, described 
as “the operation of  the 21st century”, has delivered 
benefit to millions of  patients and has been deemed 
to be extremely cost-effective (11, 12). It is anticipated 
that further improvements of  PROMs is unlikely to be 
delivered by further improvisation with implants but will 
probably result from making sure the right operation is 
performed for the right patient at the right time (112). 
If  healthcare professionals and patients are able to make 
these decisions using the information available and 
analysed in a structured and a safe way then this can be 
seen as of  huge benefit for the not only the individual 
patient but also the society. The cost of  dealing with 
postoperative adverse events or complications can 
outstrip the cost of  the primary intervention. If  we can 
avoid sentiments such as “all surgery was necessary with 
exception of  the initial intervention”, reducing harm as 
a result of  a shared decision-making tool based on the 
results of  the research based on well validated studies 
then both the individual as well as the society can be 
considered winners and can be considered a victory for 
ethical driven research and innovation.
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Total hip replacement
One in four people are predicted to suffer from 
symptomatic hip OA in at least one joint by the time 
they reach 85. In addition, today’s expectations and 
demands to remain living a painfree and mobile life is 
making it clear that there will be an ongoing reliance on 
hip replacement surgery for the foreseeable future (1). 
Different outcomes following hip replacements are 
possible and unfortunately surgical teams are not 
always able to match patients’ expectations and deliver 
the surgical ideal and outcome aimed for (24, 117). A 
well-functioning, everlasting and painless artificial joint, 
without risk to life and health would be an ideal outcome 
but it is obvious that this ideal, with a “forgotten 
hip” (118), cannot always be achieved. Potential 
unsatisfactory outcomes are perioperative or premature 
death, adverse events, re-admissions, revisions and other 
types of  re-operations. These unplanned events occur in 
a minority of  patients. Poor patient-reported outcome 
scores are more likely to occur and patient’s expectations 
are not matched. Despite advances in technology and 
the utilization of  newer implants, improved technology, 
the use of  navigation, patient-specific instrumentation 
(PSI) and robotics the outcomes of  joint replacements 
might not have improved as much as expected and its 
clinical benefits still need to be evaluated (111, 119–123). 
Revisions and re-operations come at a huge expense 
for the patient both from a financial point of  view 
as well as suffering. Revisions carry a further risk of  
subsequent revisions and reoperations. The implant 
survival is considerably lower in multiply revised joints 
than primary or first revisions procedures and in many 
cases the operations are performed for the same reasons 
as the original revision (124). PROMs are significantly 
worse following subsequent operations and there is 
higher inherent 30-and 90- day mortality after a revision 
procedure. It additionally places a tremendous burden 
on the provision of  healthcare and comes at a huge 
cost for the society. The mean cost of  a revision has 
been estimated in the USA as $ 77,851 (125). With an 
increase in demand, an ageing population with increased 
comorbidities, increased life expectancy, and higher 
expectations at the time of  both primaries and revision 
procedures, mechanisms to mitigate future revision 
procedures must be explored.
Discussion
Registers and linkage
In the initial phases this project has been concentrating 
on the development and the fine-tuning of  the tools 
to investigate the longitudinal outcome, i.e. the theme 
of  this research. The work describing the merger of  
the SHAR databases with the different administrative 
databases of  the different government organisations 
into a single research database was published in BMC 
musculoskeletal medicine (64). It was obvious from 
previous work that there was a need to include socio-
economic factors, patient-related factors as well as 
surgical-related factors when analyzing potential 
outcomes following THR and the advantages of  a 
linked research database was the obvious solution. 
Berry describes in his annotation titled “Joint Registries, 
what can we learn in 2016” that registries can provide 
the orthopaedic community with a real-time observation 
of  changes in practice (49). In our trends work we have 
identified some changes in practice during the study period. 
Whilst Sweden has always been conservative in implant 
choice and has embraced “the stepwise introduction” of  
new technologies and techniques, there has been a change 
in implant choice towards a 32 mm headsize, an increased 
use of  highly cross-linked poly-ethylene, and a move 
towards uncemented implants, especially in the younger 
population group. An important change in indication for 
surgery has been identified with a trend towards operating 
on younger, more obese and less healthy patients. Despite 
these challenges and the changes the long-term outcome 
seems to be further improving with a reduction in early 
postoperative mortality, a significant decrease in 2-year 
reoperation and revision rate. There seems to be however 
an increase in short term (30 and 90-day) re-operation and 
revision rate and that should be the subject of  a further 
in-depth investigation to ascertain the cause(s). The 
increase in early revisions within Sweden is in agreement 
with the study of  Pedersen and Thiens using the NARA 
database (126, 127). This increase in early reoperation 
and revision rate and its potential important impact on 
lifetime health risk will need to be further studied. The 
importance of  cross-referencing data between registries 
for validation has been suggested (49). Whether or not 
the increase in early reoperation and revision rate is 
solely associated with the increased use of  uncemented 
implants and the increased risk of  early (intraoperative) 
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periprosthetic fractures and the tendency of  dealing with 
early prosthetic joint infections surgically will have to be 
confirmed, but currently this is considered to be the most 
likely explanation.
We have identified an increasing satisfaction as measured 
with postoperative PROMs. This a very positive 
development and likely caused by improvements in 
surgical techniques, changes in perioperative care with 
increased attention to preoperative patient education and 
ability to manage patient expectations.
Mortality and relative survival
Whilst death is extremely rare (<0.4%) within the first 
30 days after surgery and the overall mortality rates are 
improving, it is still important to consider this outcome 
in both primary as well as revision surgery. We are aware 
of  the effects of  comorbidity, as measured by presence 
or absence of  comorbidity, ASA scores, or comorbidity 
indices, on peri- and postoperative mortality. With an 
increased attention to self-rated health, these measures 
could well be useful in predicting mortality. The 
feasibility and usability of  PROMs in the preoperative 
setting seem to be gaining momentum and are now part 
of  the routine preoperative assessment in Sweden (128, 
129). The association between the risk of  dying in the 
postoperative period (up to 5 years postoperative) and 
the prospectively collected PROMs (EQ-5D, EQ VAS 
and pain VAS) at the time of  surgical work-up, can be 
used in the preoperative discussion with patients and has 
got implications in the decision-making process. It was 
evident from the analysis that patients who report poor 
mobility and/or who are struggling with self-care are at 
an increased risk of  dying following the surgery. Whilst 
we suggest there is an association between preoperatively 
recorded PROMs and mortality it would probably need 
a randomized controlled trial (RCT) to prove causation. 
This however could be considered to be an impossible 
undertaking and could even be considered unethical. 
The main reasons to offer patients a new hip are to 
provide them with an improved mobility and improved 
quality of  life as well as the reduction of  pain. Denying 
patients potentially life-changing surgery on the basis of  
reduced mobility would be counterintuitive. I do believe 
it is however important to discuss the increased risk of  
death with the patient in the preoperative setting and it 
might be important for the health care decision makers 
to recognize that besides the fact there is an increased 
cost to the patient and the society of  waiting for surgery, 
a further deterioration of  the mobility might impact on 
the changes of  survival following surgery.
We also confirmed the diagnosis-specific differentiation 
of  relative survival rates following total hip replacement. 
Patients with primary osteoarthritis as the main indication 
for their THR have a higher survival rate compared to 
other diagnoses and the survival rate is also significantly 
higher than the general population during our studied 
time period. Patients who underwent total hip 
replacement due to sequelae of  a childhood hip disorder 
have similar survival rate to the general population while 
patients with femoral head necrosis, inflammatory joint 
disease and trauma induced secondary osteoarthritis had 
significantly lower relative survival rates. With exception 
of  a non-significant difference in survival rate in patients 
undergoing a THR for sequelae of  childhood diseases, 
our findings are in line with the findings of  Lie et al. (130). 
A recent analysis using Danish healthcare registers have 
identified an increased risk of  dying of  patients with RA 
undergoing THR, compared to patients with OA (131). 
Of  the studied fixation techniques cemented, hybrid and 
reverse hybrid had similar survival rate. Patients with 
uncemented prosthesis had a better survival. This finding 
requires some caution as the average age for patients with 
cemented prosthesis was 70 years while patients where an 
uncemented implant was used were on average 55 at the 
time of  their primary operation. Whilst we have attempted 
to adjust for age this can be considered difficult as such 
differences cannot be easily and correctly adjusted, 
because of  the excessive difference in mean age at the 
time of  surgery. The difference between the regression 
analysis, the Kaplan-Meier survival graph and the relative 
survival rate have confirmed our suspicions that the age 
at the time of  surgery could well have a bigger influence. 
If  one would only study the relative survival graph it 
would be tempting to think that cement has a protective 
effect after the initial period of  excess mortality, but this 
is likely due to increased effect of  patient selection in 
the older age group. The increased mortality in the early 
postoperative period in the patients receiving a cemented 
implant has once again been demonstrated but is reversed 
between 50 and 60 days. This finding has been studied in 
more detail by Garland et al using a different cohort of  
patients with an excess mortality in the early postoperative 
period when cemented stems were used (132). A more 
detailed study on the effects of  fixation on reoperation, 
revision and mortality might well be necessary to provide 
the necessary answers to this question. However it is 
unclear whether or not the final answer will ever be clear. 
Osteoporosis has been considered a powerful predictor 
of  life expectancy (133, 134). There is the profound 
effect of  selection bias related to bone condition and 
physiological age which cannot be controlled for. 
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Multi-state analysis
Using the MS analysis and after adjustment we have to 
contradict some studies on the effect of  approach on 
mortality and revision risk (135, 136). We found there 
was no influence of  the approach on the risk of  dying 
or revision surgery at 1 or 10 years. For this study we did 
not take the PROMs into consideration and we are well 
aware of  some studies highlighting improved PROMs 
with a posterior approach at short and long term.
We found that having lower completed levels of  
education and being widow or single had an adverse 
effect on survival. The effect of  socioeconomic factors 
have been long recognised (137). A recent study 
concluded that mortality, attributable to lower levels 
of  completed education, is comparable in magnitude 
to mortality attributable to individuals being current 
rather than former smokers and the association between 
education and mortality could be causal (138). Likewise 
it is well known that widowers have higher mortality 
rates than married people (139) and that married people 
have a longer life expectancy, compared with unmarried 
persons (140, 141). 
As expected the higher a patient scored on the ECI the 
stronger the association with mortality becomes. The 
ECI ranks highest among different comorbidity indices 
that have the ability to predict long term mortality (142). 
In a different study from looking at the predictive value 
of  comorbidity indices however we found that the 
predictive value of  the indices was poor and less good 
than age and sex (143). 
Interpretation and ramifications
The results of  the present study, based on a nationwide 
prospective collection of  data can largely uphold 
the findings in the literature and the perception of  
clinicians. Namely, that total hip replacement patients 
have a better survival that the general population. A 
common reasoning behind this is the patient selection 
and perioperative work-up. Generally in order to have 
a hip replacement surgery patient need to be in good 
health or will have some measures to improve their 
health status as part of  their perioperative work-up for 
surgery. 
I have been able to establish that the principal diagnosis 
for performing the surgery influences the relative 
survival. However there is no information about 
mortality in these patient groups, should they not 
undergo a total hip replacement.
So far I believe we will be able to use this high quality 
and validated data to provide some answers to questions 
of  longevity and complications. Further and ongoing 
analysis will in my view be able to provide answers 
towards “the million dollar question” of  providing the 
right implant and surgical intervention for the right 
patient in the right setting at the right time and the 
development of  a SDM tool.
In view of  the anticipated increase in demand of  hip 
replacement surgery due to the increased global burden 
of  hip OA it will become more than ever necessary to be 
able to use the surgical and financial resources wisely to 
the benefit of  the patients with painful hips, a decreased 
mobility and a poor quality of  life caused by an intrinsic 
hip problem.
Despite all the information available in this dissertation 
and the literature the decision to proceed or not 
to proceed with joint replacement surgery should 
not be taken lightly and only on the basis of  the 
patient preferences and following an assessment of  
the balance between benefits and potential risks or 
complications (144, 145). The results of  my research 
illustrate the possible pathways and risks associated 
with hip replacement surgery. These pathways and the 
factors influencing the outcome have, in my opinion, 
been presented in a comprehensive and pedagogic 
way. The information and the way this information is 
graphically represented, could be helpful for clinicians, 
patients and their interactions. It is recognized that a 
joint replacement usually is a life-changing procedure. 
If  performed on the right patient with the right 
expectations, for the right reasons, in the right setting 
with the right implant and technique it is extremely likely 
to be successful in the long-term. 
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I Combining administrative databases with the SHAR database is possible 
and provides variables not routinely collected in the arthroplasty registers.
II Despite the changes in patient-related characteristics and changes in surgical 
techniques, the outcomes of  THR (mortality, revision rate, PROMs) are 
 improving.
III Worse preoperative patient-reported health status is associated with an 
 increased mortality up to 5 years post surgery.
IV Hip replacement patients, who underwent their surgery electively and because 
of  primary OA, have an overall improved relative survival rate compared to 
a birth year- and sex-matched population and a low risk for revision.
V Multi-state analysis allows us to depict the hip-related timeline for patients 
undergoing elective surgery. The contralateral operation is the most likely 
next state and is seven times more likely than a revision procedure.
Conclusions
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I anticipate some further research into the identification 
of  patients undergoing multiple revisions as well as 
extending the length of  follow-up far beyond the 
current maximum of  up to14 years. With an ageing 
population and a trends towards surgery at younger 
age, it is imperative to extend the follow-up period and 
analyse the outcomes of  hip replacement surgery well 
into the second and third decade.
The four most common reasons for reoperations/
revisions following surgery are mainly aseptic loosening, 
dislocation/instability, infection, and periprosthetic 
fracture. It is necessary to explore whether there is an 
increased risk of  unsatisfactory outcomes and further 
contacts with the healthcare providers as a result 
of  the reoperation/revision for similar or different 
reasons than the reason of  failure of  the implant at 
the time of  first revision. Despite the anticipation 
that the information about (re-)revisions following 
aseptic loosening is likely to be complete and relatively 
accurate, there is an awareness of  incomplete data for 
subsequent operations for dislocation/instability as 
closed reductions will not necessarily be recorded in the 
SHAR. This is also the case for surgical treatment for 
infections and periprosthetic fractures as some of  these 
interventions are not recorded in the SHAR databases 
especially if  no exchange of  components has taken 
place. Despite all the efforts from the team at SHAR, 
we realize that no complete information is available for 
patients undergoing further surgery within SHAR for 
the above reasons but the information might well be 
obtained using the linked database and patient from the 
NPR. Identifying the right codes for readmissions and 
adverse events and when and if  necessary analyzing the 
patients notes retrospectively might well be providing 
the right answer and providing a more detailed and 
accurate picture of  the problems of  adverse events and 
readmissions not necessitating exchange of  implanted 
components.
Future and ongoing projects
The effect of  comorbidity like diabetes, inflammatory 
arthritis, and specific neurological diseases, such as 
epilepsy and Parkinson’s disease on outcomes following 
THR deserves a further investigation if  we want to 
provide the patient with the right information prior 
to surgery. Identification of  these patients within the 
database has been proven to be possible and is underway. 
Currently we are analyzing and discussing the different 
methods to perform an in-depth analysis such as exact 
matching, propensity score matching or we could revert 
as in paper V to a MS analysis, using only the selected 
cohort of  patients.
In this thesis we have concentrated on THR for 
elective reasons, however the SHAR there is a wealth 
of  information on hip replacement surgery for hip 
fractures. Multi-state analysis techniques could be used 
to study the effect of  (early) revision or reoperation 
on mortality in this patient group. In a next phase I 
would like to study the impact of  neurologic diseases 
on outcomes of  hip replacement surgery following 
hip fracture as it is anticipated there could well be an 
increase patients suffering from neurological conditions 
(for example Parkinson’s disease, dementia) fracturing 
their hip and needing acute surgery. I believe that 
avoiding complications and reoperations might even be 
more important in these frail patients, presenting with 
an acute hip fracture.
The effect of  fixation of  the femoral implants on the 
early mortality has been investigated in great detail. It 
is known that cementing the femoral component might 
be protective of  revision surgery on the short term. 
However further long term studies are necessary to 
understand to complete impact of  early revisions in 
the case of  periprosthetic fractures and the risk of  late 
periprosthetic fractures in the ageing population at risk 
of  developing osteoporotic fractures.
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Summary in English 
Longitudinal outcomes following 
 total hip replacement
Time trends, sequence of events and 
study of factors influencing implant 
survival and mortality
Osteoarthritis of  the hip is a common debilitating and 
symptomatic joint disease. The disabling symptoms 
can be successfully treated with a total hip replacement 
(THR). It is known that the majority of  patients are 
doing well following surgery, however some patients will 
need further surgery on the same or on the other hip or 
die prematurely in the perioperative period. The causes 
leading to further surgery for patients and mortality are 
multifactorial. The following are important factors in 
defining the risk for an individual patient: indication for 
surgery, complexity of  operation, patient age, medical 
comorbidities, physical activity and socio-economic 
factors, types of  implants used, surgical techniques 
employed, as well as perioperative protocols and post-
operative treatment.
The research questions for this project were: 
1. Has there been a change in patient-related, surgery-
related and socioeconomic factors in patients 
undergoing elective hip replacements and have the 
various outcome parameters evolved? 
2. Is there an association between self-reported 
health status and mortality following elective hip 
replacement? 
3. Have patients who underwent THR a better relative 
survival than the general survival and is this influenced 
by the diagnosis for which the THR was undertaken? 
4. What is the long-term risk of  subsequent surgery on 
the same or the opposite hip and risk of  mortality 
after an elective primary THR? Is there an influence 
of  patient-related, surgery-related and socio-
economic factors on subsequent surgery and dying? 
Patient level data concerning many of  these factors 
are available in the Swedish Hip Arthroplasty Register 
and administrative databases of  the National Board 
of  Health and Welfare and Statistics Sweden. This 
information was linked into a single research database. 
The principles of  relative survival analysis and multi-
state analysis with multivariable regression for statistical 
analysis were used. We decided to study patients 
undergoing elective THR between 01/01/1999 and 
31/12/2012.
Most patients were operated on because of  primary 
osteoarthritis and this share increased further during the 
period at the expense of  decreasing number of  patients 
with inflammatory OA and hip fracture. The practice 
of  elective THR has changed during the study-period, 
however despite these changes there has been a reduction 
in 30- and 90-day mortality, an overall improvement 
of  revision rates and patients have reported improved 
satisfaction and outcomes. Worse health status according 
to the EQ-5D before THR was associated with higher 
mortality up to five years after surgery. Patients with a 
THR had an improved relative survival compared to an 
age- and sex-matched population. There was a diagnosis-
specific differentiation of  relative survival rates in favor 
of  patients with hip osteoarthritis. Higher Elixhauser 
comorbidity index, level of  education and being a 
widow(er) or single, had an adverse effect on survival. 
The lifetime risk for bilateral surgery, revision and death 
was identified using the longitudinally collected data.
Despite some changes in practice, the long-term outcome 
following THR has improved. A worse self-reported 
health status is associated with increased mortality in the 
medium-term. Overall patients, undergoing an elective 
THR will have a better relative survival and a low risk 
of  revision. The risk of  receiving further surgery on the 
same or on the other hip is multifactorial, and patients 
are twice as likely to have their other hip replaced than to 
die during the study-period. Replacing the contralateral 
hip is seven times more likely than a revision procedure 
on the first implanted hip. 
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Summary in Swedish
Långsiktiga resultat efter total 
 höftprotesoperation
Tidstrender, händelsernas sekvens 
och studie av faktorer som påverkar 
 implantatöverlevnad och mortalitet 
Höftartros är en vanligt förekommande ledsjukdom som 
förorsakar smärta och nedsatt funktion. Symptomen kan 
framgångsrikt behandlas med total höftprotesoperation. 
För majoriteten har operationen avsedd effekt men 
vissa patienter behöver opereras om i samma höft eller 
på andra sidan eller dö i förtid under i samband med 
operationen. Det finns flera orsaker till varför man kan 
behöva en ytterligare operation. Viktiga riskfaktorer är: 
bakomliggande ledsjukdom, operationens svårighetsgrad, 
aktivitetsgrad, socioekonomiska faktorer, vilka implantat 
som använts, kirurgisk teknik samt vårdprocesser och 
rehabilitering i samband med operationen.
Forskningsfrågeställningarna i den här avhandlingen var:
1. Har det skett någon förändring i patientrelaterade, socio-
ekonomiska eller kirurgiska faktorer bland patienter 
som genomgått planerad total höftprotesoperation och 
hur har utfallsparametrarna förändrats?
2. Finns det något samband mellan patientrapporterade 
utfallsmått och dödlighet efter planerad total 
höftprotesoperation bättre överlevnad än patienter?
3. Har patienter som genomgått planerad total 
höftprotesoperation bättre överlevnad än 
normalbefolkningen?
4. Vilken är långtidsrisken för om operation på samma 
sida eller operation på andra sidan efter planerad 
total höftprotesoperation? Hur påverkar patient-
relaterade, kirurgiska och socioekonomiska faktorer 
risken för ytterligare operationer eller att dö.
Data på individnivå avseende dessa faktorer finns till- 
gängliga i Svenska Höftprotesregistret, Social styrel sens 
hälsodataregister och i Statistiska Central byråns regis-
ter. Information från dessa register sam bear betades 
till en forskningsdatabas. Principerna för relativ över-
levnadsanalys och ”multi-state” analys med multivariabel 
regression användes vid statistiska beräk ningar. Vi 
under sökte patienter som genomgått planerad total 
höftprotesoperation mellan 1999-01-01 och 2012-12-31.
De flesta patienterna opererades på grund av primär 
artros och den andelen ökade på bekostnad av minskad 
andel patienter med inflammatorisk ledsjukdom. 
Höftproteskirurgin har förändrats under studieperioden 
och resultaten visar att dödlighet inom 30 och 90 dagar 
har minskat, revisionsfrekvensen (om operation med 
byte av protesdelar) har minskat och patientrapporterade 
utfallsmått har förbättrats.
Sämre hälsotillstånd mätt med EQ-5D före total 
höftprotesoperation var förenat med högre dödlighet 
upp till fem år efter operationen. Patienter med total 
höftprotesoperation hade bättre relativ överlevnad jämfört 
med en ålders- och könsmatchad normalbefolkning. 
Det fanns en diagnos-specifik differentiering av relativ 
överlevnad till förmån för patienter med primär 
höftartros. Högre samsjuklighet mätt med Elixhausers 
komorbiditesindex, låg utbildningsgrad och att vara 
änka/änkling eller ensamstående hade negativ inverkan 
på överlevnad. Livstidsrisken för att behöva opereras på 
andra sidan, genomgå revision eller att dö identifierades 
med hjälp av longitudinellt insamlad data.
Det har skett förändringar inom höftproteskirurgin och 
långtidsresultaten har förbättrats. Sämre hälsotillstånd 
var förenat med ökad dödlighet på medellång sikt. 
Sett till hela populationen som genomgick planerad 
höftprotesoperation, var den relativa dödligheten 
lägre och risken för att behöva revision var låg. Många 
faktorer avgör risken att behöva opereras i andra höften 
eller att genomgå revision och under studieperioden var 
sannolikheten att opereras i andra höften dubbelt så 
hög som risken att dö. Sannolikheten att byta ut andra 
höften var sju gånger större än att behöva genomgå en 
revision i den första opererade höften. 
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Summary in Welsh
Deilliannau hydredol yn dilyn 
 ailosodiad clun  
Tueddiadau dros amser,  dilyniant o 
ddigwyddiadau ac astudio y  ffactorau 
sy’n dylanwadu ar goroesiad 
 mewnblaniad a marwolaethau 
Mae osteoarthritis yn y glun yn glefyd cyffredin, sy’n 
wanhaol ac yn symptomatig. Mae’r symptomau yn 
anablu, a gellir eu trin yn llwyddiannus trwy osod clun 
newydd (THR). Gwyddom fod y mwyafrif  o’r cleifion 
yn gwneud yn dda yn dilyn y llawdriniaeth; fodd bynnag 
bydd ar rai cleifion angen llawdriniaeth bellach ar yr un 
glun neu ar y glun arall. 
Mae’r ffactorau achosol sy’n arwain at lawdriniaeth 
bellach ar gyfer cleifion, yn ogystal ag at farwolaeth, yn 
niferus. Mae’r canlynol yn ffactorau pwysig o ran diffinio’r 
risg ar gyfer claf  unigol: arwydd bod angen llawdriniaeth, 
pa mor gymhleth yw’r llawdriniaeth, oedran y claf, 
cydafiachusrwydd meddygol, gweithgarwch corfforol 
a ffactorau economaidd-gymdeithasol, y mathau o 
fewnblaniadau a ddefnyddir, y technegau llawfeddygol 
a ddefnyddir, yn ogystal â’r protocolau amdriniaethol a’r 
driniaeth ar ôl y llawdriniaeth. 
Roedd y cwestiynau ymchwil ar gyfer y prosiect hwn fel 
a ganlyn: 
1. A fu unrhyw newid o ran y ffactorau sy’n ymwneud 
â’r claf, y ffactorau sy’n ymwneud â’r llawdriniaeth, 
a’r ffactorau economaidd-gymdeithasol ar gyfer 
y cleifion sy’n dewis cael clun newydd, ac a yw 
paramedrau amrywiol y canlyniadau wedi esblygu? 
2. A oes yna gysylltiad rhwng statws iechyd 
hunangofnodedig a marwolaeth yn dilyn triniaeth 
ddewisol i gael clun newydd? 
3. A yw cyfraddau goroesi cymharol cleifion a gafodd 
THR yn well na’r gyfradd oroesi gyffredinol, ac a yw’r 
diagnosis a arweiniodd at y THR yn effeithio ar hyn? 
4. Beth yw’r risg hirdymor o ran llawdriniaeth ddilynol 
ar yr un glun, neu ar y glun arall, yn ogystal â’r risg o 
farwolaeth, yn dilyn THR cynradd dewisol? A yw’r 
ffactorau sy’n ymwneud â’r claf, y ffactorau sy’n 
ymwneud â’r llawdriniaeth, a’r ffactorau economaidd-
gymdeithasol yn effeithio ar lawdriniaeth ddilynol 
neu farwolaeth? 
Mae data lefel y claf, sy’n berthnasol i nifer o’r ffactorau hyn, 
ar gael ar Gofrestr Cymalffurfiad y Glun Sweden, ac yng 
nghronfeydd data Bwrdd Cenedlaethol Ystadegau Iechyd 
a Lles Sweden. Cafodd yr wybodaeth hon ei chysylltu i 
greu un gronfa ddata ymchwil. Defnyddiwyd egwyddorion 
dadansoddiad o oroesiad cymharol a dadansoddiad amlgyflwr 
gydag atchweliad amlnewidynnol ar gyfer dadansoddiad 
ystadegol. Penderfynwyd astudio cleifion a gafodd THR 
dewisol rhwng 01/01/1999 a 31/12/2012. 
Cafodd y mwyafrif  o’r cleifion lawdriniaeth o ganlyniad 
i osteoarthritis sylfaenol, a chynyddodd y dangosydd 
hwn ymhellach yn ystod y cyfnod, a hynny ar draul nifer 
gostyngol o gleifion a oedd yn dioddef  o osteoarthritis 
ymfflamychol a thoriadau clun. Mae’r arfer o gynnal 
THR dewisol wedi newid yn ystod y cyfnod astudio; 
fodd bynnag, er gwaethaf  y newidiadau hyn, mae 
gostyngiad wedi bod o ran marwolaethau mewn 30 a 
90 o ddiwrnodau, yn ogystal â gwelliant cyffredinol o 
ran y cyfraddau adolygu, ac mae’r cleifion wedi cofnodi 
gwell boddhad a chanlyniadau. Roedd statws iechyd 
gwaeth cyn THR, yn ôl yr EQ-5D, yn gysylltiedig â nifer 
uwch o farwolaethau, a hynny hyd at bum mlynedd ar 
ôl y llawdriniaeth. Roedd goroesiad cleifion a oedd wedi 
cael THR yn well o gymharu â phoblogaeth o’r un oed 
a rhyw. Roedd gwahaniaethiad diagnosis-benodol o’r 
cyfraddau goroesi cymharol yn dilyn THR yn ffafrio 
cleifion ag osteoarthritis yn y glun. Roedd mynegrif  
cydafiachusrwydd Elixhauser uwch, lefel addysgol, a bod 
yn weddw neu’n sengl, wedi cael effaith andwyol ar y 
siawns o oroesi. Nodwyd y risg oes ar gyfer llawdriniaeth 
ddwyochrog, adolygiad a marwolaeth gan ddefnyddio’r 
data a gasglwyd mewn modd hydredol. 
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Er gwaethaf  rhai newidiadau o ran arfer, mae’r canlyniad 
hirdymor yn dilyn THR wedi gwella. Mae statws iechyd 
hunangofnodedig gwaeth yn gysylltiedig â marwolaeth 
yn y tymor canolig. Yn gyffredinol, bydd cleifion sy’n 
cael THR dewisol yn goroesi’n well, yn gymharol, a bydd 
yna risg isel y bydd yn rhaid cynnal adolygiad. Mae yna 
nifer o ffactorau sy’n ymwneud â’r risg o lawdriniaeth 
bellach ar yr un glun neu ar y glun arall, ac mae cleifion 
ddwywaith yn fwy tebygol o gael ail glun newydd nag 
y maent o farw yn ystod y cyfnod astudio. Mae cael 
llawdriniaeth ar y glun gydgyferbyniol seithwaith yn fwy 
tebygol na chael triniaeth adolygol ar y glun gyntaf  a 
fewnblannwyd. 
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Summary in Dutch
Longitudinale evolutie na totale 
 heupprothese.
Tendens, opeenvolging van 
 gebeurtenissen en analyse van  factoren 
die het behoud van de prothese en de 
sterfte bepalen.
Artrose van de heup is een frequent voorkomende, 
slepende en symptomatische gewrichtsaandoening. 
Het is algemeen bekend dat de symptomen van het 
gewrichtslijden succesvol kunnen behandeld worden 
door het plaatsen van een artificieel heupgewricht. Het 
merendeel van de patiënten doet het uitstekend na de 
ingreep. Er zijn echter patiënten die verdere ingrepen 
moeten ondergaan aan de heup, aan dezelfde of  aan 
de tegenovergestelde zijde ,of  vroegtijdig sterven in de 
perioperatieve periode.
De factoren die leiden tot verdere ingrepen of  tot 
een vroegtijdige dood zijn multifactorieel bepaald. De 
volgende factoren zijn belangrijk bij het bepalen van 
het risico voor een individuele patiënt: indicatie voor 
chirurgie, complexiteit van de ingreep, leeftijd van de 
patiënt, medische comorbiditeiten, lichamelijke activiteit, 
socio-economische omstandigheden, type implantaat, 
chirurgische technieken, alsook het perioperatieve 
protocol en de postoperatieve behandeling.
De onderzoeksvragen voor dit project waren: 
1. Is er een evolutie in de patiëntgerelateerde, chirurgi-
egerelateerde en sociaal-economische factoren 
bij patiënten die een geplande heupchirurgie 
onder gaan en in welke mate zijn de verschillende 
uitkomstparameters mee geëvolueerd? 
2. Is er een associatie tussen zelf-gerapporteerde 
gezond heidstoestand en overlijden na electieve heup-
prothese chirurgie? 
3. Hebben patiënten die een geplande heup prothese-
chirurgie hebben ondergaan een betere relatieve 
overlevingskans dan de doorsneebevolking en is dit 
verschil in overleving beïnvloed door de indicatie 
waarvoor de ingreep werd ondernomen? 
4. Wat is het langetermijnrisico voor verdere chirurgie 
op dezelfde of  de tegenovergestelde heup en wat is 
het risico voor overlijden na een electieve ingreep? Is 
er een invloed van de patiëntgerelateerde, chirurgie-
gerelateerde en socio-economische factoren op de 
daaropvolgende operaties en overlijden?
Patiëntengegevens omtrent deze factoren zijn beschikbaar 
in het Zweeds Heup Implantaat Register (SHAR) en in 
de administratieve databases van de Nationale Raad voor 
Volksgezondheid en Welzijn (Socialstyrelsen) en Statistiek 
Zweden (SCB). De informatie werd samengebracht in 
een gecombineerde onderzoeksdatabank. De principes 
van relatieve overlevings- en multistaatanalyse met 
multivariabele regressie werden gebruikt als statistische 
methodologie. Patiënten, die electief  tussen 01/01/1999 
en 31/12/2012 werden geopereerd, waren het onderwerp 
van dit studieproject.
Het merendeel van de patiënten onderging de ingreep 
omwille van primaire artrose en er was een toename 
in die indicatie tijdens de studieperiode ten nadele van 
een vermindering in patiënten geopereerd omwille 
van een inflammatoire pathologie. Gedurende de 
studieperiode was er een evolutie in de chirurgische 
praktijk, maar ondanks de wijzigingen is er een daling 
in de mortaliteit na 30 en 90 dagen, een daling van 
het aantal reoperaties en in het algemeen is er een 
verbeterde tevredenheid en uitkomstparameters. Een 
mindere gezondheidstoestand volgens de EQ-5D in 
de preoperative periode is geassocieerd met een hogere 
kans op overlijden tot vijf  jaar na de operatie. Patiënten 
hebben een betere relatieve overleving na het ondergaan 
van een electieve heupoperatie waarbij het gewricht 
wordt vervangen. Er is een diagnosespecifiek verschil 
in relatieve overleving afhankelijk van de reden voor 
de ingreep waarbij patiënten met een degeneratieve 
reden voor de heupartrose het beter doen.. Hogere 
Elixhauser comorbiditeitsindex, een lager behaald 
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niveau van onderwijs en niet –samenlevend zijn, hebben 
een negatieve invloed op de overlevingskansen. Het 
levenslange risico voor bilaterale chirurgie, revisie en 
dood werden bepaald op basis van de longitudinale 
verzamelde gegevens.
Ondanks enkele veranderingen in de praktijk zijn de 
resultaten op lange termijn nog steeds aan het verbeteren. 
Een mindere preoperatieve gezondheidstoestand is 
geassocieerd met een verhoogde kans op overlijden 
op de middellange termijn. In het algemeen, hebben 
patiënten na een geplande ingreep een betere relatieve 
overleving en een geringe kans op een reoperatie. Het 
risico op een verdere operatie aan dezelfde of  de andere 
heup is multifactorieel bepaald en patiënten hebben 
dubbel de kans op een operatie waarbij de andere 
heup wordt vervangen dan te overlijden tijdens de 
studieperiode. Het vervangen van de contralaterale heup 
is 7 keer meer voorkomend dan een heringreep van de 
eerste geïmplanteerde heup.
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